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RESUMO 
Introdução: Os homens que têm sexo com homens (HSH) têm sido, desde o início da 
epidemia do vírus da imunodeficiência humana (VIH), uma população especialmente 
afetada pela infeção. Estimativas recentes mostram que nos países ocidentais a 
epidemia está a ressurgir nesta população. Em Portugal, após vários anos de uma 
epidemia maioritariamente associada ao consumo inseguro de drogas pela via 
injetada, a transmissão associada ao sexo entre homens tem vindo a ganhar 
relevância. Torna-se assim essencial o estabelecimento ferramentas de vigilância 
epidemiológica que permitam abordagens quer descritivas quer analíticas da 
distribuição e dos determinantes da infeção VIH nos HSH. Neste contexto foi 
implementado um estudo de coorte prospetivo – a Lisbon Cohort of MSM – localizado 
num centro comunitário para rastreio rápido do VIH e aconselhamento dirigido a HSH. 
O principal objetivo da coorte é monitorizar de forma dinâmica a carga da doença e os 
seus preditores. Também se espera que este estudo de coorte possa produzir 
informação importante para a melhoria dos serviços de teste e para a garantia de uma 
ligação atempada aos cuidados de saúde. 
Objetivos: Descrever a Lisbon Cohort of MSM através dos seguintes objetivos: 1) 
descrever o desenho e as opções metodológicas do estudo, assim como as 
características dos participantes à entrada no estudo; 2) estimar a incidência da 
infeção VIH e testar as mudanças nas exposições a curto prazo como preditores da 
seroconversão. 
Métodos: Foi estabelecido um estudo observacional prospetivo – a Lisbon Cohort of 
MSM – que funciona num centro comunitário para rastreio rápido do VIH e 
aconselhamento em Lisboa (CheckpointLX). Os homens que têm um teste não reativo, 
com idade igual ou superior a 18 anos, que reportam já ter tido sexo com outros 
homens são convidados a participar no estudo e são agendadas visitas de seguimento 
de acordo com a sua disponibilidade, idealmente com intervalos de seis meses. Cada 
avaliação no âmbito da coorte compreende a aplicação de um questionário estruturado 
e de teste rápido para o VIH e para a sífilis realizados por pares. As características dos 
participantes à entrada no estudo foram descritas através de frequências absolutas e 
proporções no caso de variáveis categóricas e de médias e desvios-padrão ou 
medianas e os percentis 25 e 75 no caso de variáveis contínuas. As taxas de 
incidência (IR) e os respetivos intervalos de confiança a 95% (IC 95%) foram 
calculados usando como denominador o total de pessoas-ano em risco. Os preditores 
da seroconversão foram identificados usando a regressão linear generalizada com 
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distribuição de Poisson e as associações apresentadas como razões de taxas de 
incidência (IRR) e respetivos IC 95%. Os dados analisados referem-se ao período de 
abril de 2011, data de início do estudo, a fevereiro de 2014.  
Resultados: Objetivo 1: Durante o período selecionado apresentaram-se no 
CheckpointLX 3106 HSH elegíveis para entrada na coorte dos quais 923 (29.7%) 
recusaram participar. Os restantes 2183 (70.3%) HSH foram incluídos no estudo e 804 
tinham pelo menos uma visita de seguimento, num total de 893 pessoas-ano de 
observação. Cerca de 82.3% dos participantes já tinha feito um teste ao VIH 
anteriormente, sendo os motivos mais referidos para o teste atual: conhecer o estado 
de saúde/teste de rotina (81.3%); perceção de exposição ao VIH há mais de 3 meses 
(50.5%) e nos últimos 3 meses (40.7%). Cerca de 12% dos HSH reportaram relações 
sexuais com homens VIH-positivo nos 12 meses anteriores à entrada no estudo. 
Aproximadamente 8% dos participantes que reportaram terem tido pelo menos um 
parceiro habitual referem que este era VIH-positivo, e destes 43.7% reportaram o uso 
inconsistente do preservativo. Dos que desconheciam o estatuto serológico do 
parceiro habitual 71.0% reportaram o uso inconsistente do preservativo. Dos HSH que 
tiveram pelo menos um parceiro ocasional, cerca 21% reportaram não ter usado o 
preservativo na última penetração anal e 46.4% reportaram o uso inconsistente do 
preservativo nos 12 meses anteriores à entrada na coorte. A razão mais referida para 
o não uso do preservativo na penetração anal foi a existência de um parceiro habitual 
(66.2%). O consumo de álcool ou drogas antes ou durante as relações sexuais nos 12 
meses anteriores à entrada na coorte foi referido por 86.4% dos participantes. Objetivo 
2: Durante o período de seguimento verificam-se 25 seroconversões, resultando numa 
incidência de 2.80 por 100 pessoas-ano (IC 95%: 1.89-4.14). Os HSH que 
seroconverteram tinham um maior número médio de testes por ano. A seroconversão 
estava significativamente associada à revelação do estatuto serológico positivo do 
parceiro habitual no período entre a entrada no estudo e a visita mais recente, ao 
abandono do uso consistente do preservativo nas relações sexuais anais com parceiro 
habitual durante o seguimento e ao diagnóstico de sífilis durante o seguimento. Da 
mesma forma, ter tido relações sexuais com homens VIH-positivo, ter tido um parceiro 
habitual VIH-positivo pelo menos uma vez durante o seguimento e reportar 
persistentemente ter tido relações anais desprotegidas com parceiro ocasional foram 
preditores da seroconversão.  
Conclusões: A nível nacional, o seguimento desta coorte de HSH VIH-negativos 
constituirá uma ferramenta valiosa para a monitorização dinâmica da infeção VIH num 
cenário do sul da europa onde a informação prospetiva existente tem sido muito 
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limitada. No contexto internacional irá permitir ainda uma abordagem analítica mais 
aprofundada das tendências temporais a nível populacional e da identificação das 
mudanças nos fatores de risco a nível individual que modelam a epidemia nos HSH. 
Dadas as opções no desenho do estudo não se espera que amostra seja 
representativa de toda a população de HSH no nosso país. No entanto, uma vez que 
não se esperam mudanças substanciais na magnitude do viés de seleção ao longo do 
período do estudo, acreditamos que nossas opções metodológicas não excluem a 
capacidade de estimar tendências temporais da incidência ou de identificar os 
determinantes da seroconversão. Esta primeira estimativa da incidência do VIH nos 
HSH portugueses foi mais do que a observada noutros países europeus, indicando 
uma elevada velocidade de transmissão do vírus. O presente estudo produz evidência 
de que as mudanças individuais recentes nos contextos e nos comportamentos 
durante o seguimento, as relações serodiscordantes e as relações sexuais 
desprotegidas com parceiro ocasional são determinantes particularmente importantes 
da epidemia do VIH nesta coorte de HSH. Em última instância os resultados do estudo 
servirão para informar da potencial efetividade das políticas dirigidas à redução da 
carga do VIH na população de HSH. 
4 
 
ABSTRACT 
Introduction: Men who have sex with men (MSM) have been, since the beginning of 
the HIV epidemic, a key population at higher risk. Recent trends show a resurgent 
epidemic in this population in Western countries. In Portugal after several years of a 
drug injection driven HIV epidemic, sex between men has regained relevance as a 
transmission mode. Surveillance tools that allow for a better description of the 
distribution and determinants of HIV infection in MSM are essential. In this scenario, an 
open prospective cohort study was set up - The Lisbon Cohort of MSM, at a 
community-based voluntary HIV counselling and testing service targeting the MSM 
population. The main goal of this cohort study is to dynamically monitor the burden of 
disease and its predictors. The cohort is also expected to provide important information 
to improve the provision of HIV testing and to ensure timely linkage to care.  
Objectives: We aimed to describe the ongoing Lisbon Cohort of MSM through the 
following objectives: 1) to describe the design and methodological options of the study, 
as well as the descriptive characteristics of participants at cohort entry; 2) to estimate 
incidence of HIV infection and to assess how individual short-term changes in 
exposures predict seroconversion. 
Methods: The Lisbon Cohort of MSM prospective study was set-up and conducted at a 
community-based voluntary HIV counselling and testing centre in Lisbon 
(CheckpointLX). Men testing negative, aged 18 or older who report having had sex with 
other men are invited to participate and reassessed at follow-up visits scheduled 
according to their convenience, but ideally with 6-month intervals. At each evaluation a 
structured questionnaire is administered and HIV and syphilis rapid testing are 
performed by peer counsellors. Characteristics of participants enrolled were described 
using absolute frequencies and proportions in the case of categorical variables. Means 
and standard deviation or median and percentiles 25 and 75 were used to describe 
continuous variables. Incidence rates (IR) with 95% confidence intervals were 
estimated using as the denominator the sum of person-years (PY). Predictors of HIV 
seroconversion were identified using Poisson generalized linear regression. 
Associations are presented as incidence rate ratios and 95% confidence intervals (95% 
CI). Data analysed refer to the period from April 2011, when the cohort study was 
established, to February 2014.  
Results: Objective 1: During the study period 3106 MSM were eligible to enter the 
cohort of whom 923 (29.7%) refused to participate. The remaining 2183 (70.3%) 
individuals were enrolled and 804 had at least one follow-up evaluation, for a total of 
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893 person-years of observation. HIV testing prior to cohort entry was reported by 
82.3% of participants, the most common reasons for the index HIV test were: to check 
health status/routine (81.3%), perception of exposure to HIV more than 3 months 
before (50.5%) and in the previous 3 months (40.7%). Twelve percent of MSM reported 
sexual intercourse with HIV-positive men in the previous 12 months. Approximately 
eight percent of those who reported a steady relationship had a HIV-positive partner, of 
whom 43.7% reported inconsistent condom use. That proportion was 71.0% among 
those unaware of their steady partner’s HIV status. Twenty one percent of men who 
had at least one occasional partner reported no condom use in the last sexual 
encounter and 46.4% reported inconsistent use in the previous 12 months. The most 
referred reason for engaging in unprotected anal intercourse was with a steady partner 
(66.2%). Alcohol or drugs use before or during sexual intercourse in the previous 12 
months was reported by 86.4% of participants. Objective 2: During follow-up 25 
seroconversions were observed, yielding an overall incidence of 2.80/100 person-years 
(95% CI: 1.89-4.14). Men who seroconverted had a higher mean number of tests per 
year. Seroconversions were significantly associated with partner disclosure of HIV 
status during follow-up, newly-adopted unprotected anal intercourse (UAI) with a 
steady partner and being newly-diagnosed with syphilis during follow-up. Likewise, 
sexual intercourse with HIV-positive men, having had a HIV positive steady partner at 
least once during follow-up and persistent UAI with occasional partners were predictors 
of seroconversion.  
Conclusions: At a regional level the follow-up of this cohort of HIV-negative MSM will 
be a valuable tool for the dynamic monitoring of HIV infection in a Southern European 
setting where limited prospective information existed. Within the international context, it 
will additionally allow for a deeper analytical approach on population time trends and 
individual changes in risk factors shaping the epidemic among MSM. Given our 
sampling frame, full generalizability regarding the whole MSM population is not 
expected. However, since selection bias is not expected to change substantially 
throughout the study period, we believe that our methodological option will not preclude 
the estimation of time trends in incidence estimates or of the determinants of 
seroconversion. The first estimate of HIV incidence in Portuguese MSM yielded a 
higher incidence than in other countries revealing worrying HIV transmission. The 
present study also provides evidence that short-term contextual and behavioural 
changes during follow-up and serodiscordant relationships as well as persistent UAI 
with occasional partners are likely driving the HIV epidemic in this cohort of MSM. 
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Ultimately, study results are intended to inform on the real-world effectiveness of 
policies directed to reducing the burden of HIV among MSM. 
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1. INTRODUCTION 
1.1. HIV EPIDEMIOLOGY  
In 2012 it was estimated that 35.3 (32.2–38.8) million people were living with the 
human immunodeficiency virus (HIV) worldwide, an increase from previous years due 
to the increasing life expectancy of people living with the infection (1). At the same 
time the number of new HIV infections decreased from 3.4 (3.1–3.7) million in 2001 to 
2.3 (1.9–2.7) in 2012 and the acquired immunodeficiency syndrome (AIDS) deaths 
decreased from a peak at 2.3 (2.1–2.6) million in 2005 to 1.6 (1.4–1.9) million in 2012 
(figure 1) (1).  
Figure 1: Estimated number of people living with HIV in 2012 and trends in the incidence of new infections 
from 2001 to 2012 by local region - data from UNAIDS 2013 report. Source: Maartens G. et al, 2014. 
 
In Europe HIV infection still remains of major public health importance with an estimate 
of 1.5 million people living with the infection (2). In 2012, 131 202 new HIV infections 
were reported in 52 of the 53 countries of the WHO European Region, 29 381 of which 
were in the European Union and European Economic Area (EU/EEA) (2). Surveillance 
data estimated, for 2012, an overall incidence of 7.8 diagnoses per 100 000 population 
in the WHO European Region and 5.8 per 100 000 in the EU/EEA (2). The main 
modes of transmission varied by geographical area, illustrating the diversity of the 
epidemiology of HIV in Europe; heterosexual transmission was the main mode of 
transmission in the WHO European Region, while sexual transmission between men 
was the main mode in the EU/EEA and transmission due to unsafe injecting-drug use 
remained substantial in the Eastern region (2). 
1.1.1. HIV epidemiology in MSM worldwide  
Since the first cases of what is now known as AIDS were described in 1981 in 26 
previously healthy homosexual men in New York and in California in the United States 
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(US) (3), men who have sex with men (MSM) have been a key population at higher 
risk for HIV infection. 
In 2012, the prevalence of HIV among MSM appeared to have a slight increase 
globally (1). In Europe, the proportion of HIV diagnoses reported among MSM varied 
between from 1.2% in Eastern Europe to 41.7% in Western Europe (2). Trends by 
transmission mode showed that the number of HIV diagnoses among MSM have had 
a 2.5% annual increase from 2006 to 2011 in the EU/EEA region (2). This is of 
particular concern since the largest increase in new infections has been seen among 
younger MSM (4). 
The increasing trends in new HIV cases in MSM have been described as a resurgent 
epidemic (5). Surveillance data from eight countries, with concentrated HIV epidemics 
and methodologically similar HIV case surveillance systems, Australia, Canada, 
France, Germany, Netherlands, Spain, United Kingdom (UK) and US, demonstrated a 
notably consistent pattern of changes in rates of HIV notifications among MSM in the 
past decade (6). After a decrease in reported cases from 1996 to 2000, a consistent 
increase was seen from 2000 to 2005 (6). In the US, between 2006 and 2009, the 
overall number of new HIV infections remained stable with the exception of MSM, in 
whom the estimated number of new infections increased significantly, mostly due to 
increases in HIV infection rates in young and black MSM (7). Similarly results from the 
Amsterdam Cohort Studies (ACS) showed an increase in HIV incidence in MSM from 
1.0 per 100 person-years in 1992 to 2.0 per 100 person-years in 2009 (8). In low and 
middle income countries, MSM are also at much higher risk for HIV infection than non-
MSM, with an estimated odds ratio of 10 in high prevalence countries and 60 in low 
prevalence countries (9).  
These increasing rates of new HIV notifications among MSM are unlikely to be 
explained solely by changes in surveillance practices. Neither is it expected that 
changes in HIV testing patterns among MSM could be accountable for such trends (6). 
Therefore, after excluding the most probable sources of artificial trends, observed data 
point to a true increase in the risk of infection in this population. Such findings call for 
research into accurate data and up to date quantitative estimation of the burden of new 
infections as driving the current epidemic.  
1.1.2. HIV epidemiology in MSM in Portugal 
In Portugal, by the end of 2012, there were 42 580 HIV cases notified of which 31 255 
(73.4%) were in men (10). The majority of cumulative cases were sexually transmitted, 
9 
 
43.4% of heterosexual transmission and 13.8% of sexual transmission between men. 
Unsafe use of injected drugs accounted for 37.8% of all HIV cases (10). Throughout 
the first 30 years of the HIV epidemic a change in the epidemiological patterns of 
transmission has been observed. Whereas the first 20 years most cases were related 
with unsafe injection practices, in the last decade heterosexual transmission became 
reportedly the major driver of the epidemic in Portugal (11). Nevertheless, an increase 
in the absolute number of notified cases related with sexual transmission between men 
as well as a decrease in median age of notified cases have been observed (11). 
Between 2005 and 2011 there was a 6% annual increase in the number of newly 
diagnosed HIV cases attributed to sexual transmission between men, while in the 
same period cases due to unsafe injection behaviours and heterosexual transmission 
decreased by 22% and 4% respectively (10). HIV cases notified in MSM tend to be in 
younger individuals, mostly those resident in Lisbon and those born in Portugal (11). 
The trends of increasing new cases in MSM may reflect not only higher transmission 
rates in this group but also earlier diagnosis which may result from increased self-
perception of risk and higher uptake of HIV testing (11).  
1.1.3. Implications of the current HIV epidemics in MSM 
Many accomplishments in terms of scientific advances during the past three decades 
have been achieved. Still, from this portrayal of the HIV epidemic in MSM, it is clear 
that this group remains a key population at higher risk of HIV infection, posing a 
number of challenges for the different stakeholders in this field.  
Surveillance data should be used within countries and across countries to help set 
priorities for prevention research and for allocation of resources. In fact data, suggests 
that MSM communities in North America, Western Europe, and Australia might share 
some important features that should be considered on HIV research and prevention 
efforts overcoming country-specific programs (1, 6). 
The resurgent epidemics among MSM highlights the need for additional research to 
update estimates of the incidence of HIV globally and to identify the factors that 
currently influence transmission, including risk management and sexual network 
characteristics (5, 6).  
1.2. HIV TESTING AND COUNSELLING 
HIV testing and treatment remains a cornerstone of HIV prevention and management 
(12) with major individual and public health benefits. The advent of effective 
antiretroviral therapy (ART) has improved prognosis and life expectancy and reduced 
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AIDS-related deaths of persons infected with HIV. Widespread and early access to 
treatment may reduce HIV incidence by reducing viral load at the population level, 
although this has not yet been shown for MSM (13). Nevertheless, knowledge of one’s 
HIV status has been associated with a reduction in risk behaviour in HIV-positive 
individuals (14). Early diagnosis is therefore key to ensure benefit from ART and to 
decrease HIV transmission.  
In Europe the number of late presenters, defined as patients with a CD4 count below 
350cell/µL at the time of diagnosis or ART initiation within 3 months of diagnosis (15), 
has decreased over time but remains a significant issue in all HIV exposure groups 
(16). Within the Collaboration of Observational HIV Epidemiological Research Europe 
(COHERE) network in 2011, 53.8% of all persons and 43.7% of MSM presenting for 
care were late presenters (16). A previous research that studied testing practices 
among recently diagnosed HIV-positive persons from 4 European countries including 
Portugal found an overall proportion of late diagnosis of 41% (17). Portugal had a 
higher rate of late diagnosis estimated at 63%, when compared with Estonia (10%), 
Belgium (34%) and Finland (50%) (17). Also noteworthy is the finding that most 
important barriers to testing were centred on denial of risk, indicating the need for 
raising awareness about HIV and the benefits of testing (17).  
Earlier and more widespread testing strategies targeting all populations at risk both 
within the health care system and as part of community-based programs are key in the 
response to HIV epidemics (18).   
1.2.1. Guidelines for HIV testing and counselling 
WHO guidelines for HIV testing and counselling (HTC) are that mandatory or 
compulsory testing is never appropriate. Exceptions to this however are screening for 
HIV and other blood-borne infections of all blood destined for transfusion or for 
manufacture of blood products and screening of donors prior to all procedures involving 
transfer of bodily fluids or body parts, such as artificial insemination, corneal grafts, and 
organ transplant (19).  
HTC services, regardless of the model of delivery, should adhere to the five Cs: 
Consent, Confidentiality, Counselling, Correct test results and linkage to Care (20). For 
concentrated epidemics, HIV testing and counselling should not be recommended to all 
people attending all health facilities, but rather target all adults and children who 
present with signs and symptoms suggestive of underlying HIV infection and to children 
known to have been exposed to HIV in the perinatal period (21).  
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To increase the uptake of HIV testing at the European region level, the European 
Centre for Disease Control and Prevention (ECDC) has identified a number of core 
principles for national HIV testing strategies and programmes (22):  
 HIV testing should be voluntary, confidential, and undertaken with informed 
consent;  
 access to treatment, care, and prevention services should be ensured;  
 governments need to make HIV testing a priority, which should be part of 
national strategies, developed and implemented with the participation of 
stakeholders;  
 stigma must be reduced;  
 legal and financial barriers have to be removed.   
Only a few countries indicate any national guidance detailing how often MSM should be 
screened for sexually transmitted infections (STI) and HIV, while a few others, indicate 
that guidelines are under development (23). European guidelines regarding frequency 
of HIV/STI screening for MSM are lacking, although risk-taking behaviours in MSM and 
the need to offer an increased screening frequency for these men seems to be 
recognized (23). A clearer national and pan-European guidance that provides a 
framework for risk profiling and screening intervals and more coherent and explicit 
guidelines on screening of MSM would be helpful for less experienced healthcare 
professionals and for new providers that are emerging and who may benefit from 
guidelines that require less interpretation (23).  
In Portugal HIV testing is non-mandatory, voluntary, confidential, and undertaken under 
informed consent (24). HIV testing is recommended to all patients whose clinical 
presentation may result from an underlying HIV infection, and more selectively in 
certain subpopulations that includes sexual partners of persons with a HIV diagnosis, 
MSM and female partners of MSM amongst other key populations (24). In the case of 
MSM annual testing is recommended, however frequency can be increased if an acute 
HIV infection is suspected or in case of high risk exposure to HIV (24). 
1.2.2. Type of HIV tests 
In 1985 the first HIV tests were introduced based on enzyme immunoassay (EIA) 
techniques and, shortly after, Western blot was approved to confirm HIV infection (25). 
EIAs were originally developed to screen blood for HIV and have evolved to detect HIV 
earlier during the course of infection. First and second generation EIAs detect IgG 
antibodies against HIV-1. Third generation EIAs use “antigen sandwich” techniques 
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that can also detect IgM antibodies against HIV-1, which develop earlier after infection 
(25). Fourth generation combination EIAs identify HIV infection even earlier because 
these simultaneously detect HIV antibody and p24 antigen (25, 26). 
Rapid diagnostic HIV tests are single-use EIAs that contain all necessary reagents and 
that yield results in less than 30 minutes (25). Because rapid tests have sensitivities 
and specificities similar to those of conventional EIAs, a negative result of a rapid test 
is conclusive and generally requires no further confirmatory testing. A reactive rapid 
test result requires further testing to confirm the diagnosis, usually with Western blot or 
indirect immunofluorescence assay (25, 27). The widespread adoption of rapid 
antibody tests has many advantages. Rapid HIV tests make it possible to perform the 
test in a timely manner, without the need for a return visit, thereby substantially 
increasing the number of persons who receive their test results (28) and who have 
access to effective treatment earlier (25). Rapid HIV tests are also essential when 
immediate results are necessary to make decisions about treatment (25). As rapid HIV 
antibody tests are easy-to-use they are feasible in a variety of clinical and nonclinical 
settings playing an important role in expanding access to testing (25). 
Point-of-care (POC) tests do not have a universally accepted definition but they are 
often described as any test designed to be used directly at the site of patient care 
providing a rapid result to guide clinical decisions and follow-up during the same 
encounter (29, 30). POC tests have been used in genitourinary clinics, outreach 
settings, community clinics, sex venues for MSM, and in needle and syringe exchange 
facilities. POC tests can also be used in cases of women at high risk presenting late in 
pregnancy or delivery, or in case of a non-occupational post-exposure prophylaxis 
(PEP) for recipient and possible index subjects (31). 
In order to be used in such settings the abovementioned POC tests have to meet 
specific criteria including high sensitivity and specificity (>99%) (31). These tests 
should also be reproducible, and be easy to learn, perform and read, as well as give 
accurate results and be as non-invasive as possible (31). Other important issues are 
storage conditions, such as refrigeration, and quality assurance of both the test kits 
used and procedures (31). Beyond the technical advantages of rapid tests mentioned 
above, other advantages have been described, such as high acceptability by staff and 
preference by many patients, and confirmed cost effectiveness in many situations (31). 
These tests also have the potential to overcome many of the barriers that patients 
experience in HIV testing, such as a fear of venepuncture, anxiety between the time of 
the test and the time of the result, the inconvenience of having to return for results, 
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stigma, and confidentiality issues (31, 32). These tests have also been described as 
critically improve access to HIV testing by allowing more individuals to know their HIV 
status (29). 
1.2.3. HIV testing and counselling services  
HTC services are the gateway for HIV treatment and care, as well as for prevention at 
the community level. Robust HTC services that are acceptable, accessible, and 
provide successful linkage to prevention and care services, are essential for a 
successful public health response to HIV. 
HTC services are mainly available through two delivery models - facility-based, 
(whether in clinical settings or in voluntary counselling and testing (VCT) sites), and 
community-based (20).  
The WHO defines VCT as HTC services in sites besides health-care facilities that 
have some features that make them similar to community-based services (20). VCTs 
are outside clinical settings and are usually situated in the community, and are thus 
accessible to their target populations, often offering comprehensive counselling, same-
day results, staffing, and linkages to care or prevention services (20). Nevertheless, 
because of their potential for biased coverage, client-initiated approaches should not 
be relied upon as the single strategy for offering HIV tests, but should rather be part of 
an integrated effort to promote increasing levels of HIV status awareness in the 
population (20).  
Community-based HTC as defined by the WHO are services that are home-based, 
door-to-door, index-case, mobile and outreach, workplace, and school-based (20). 
This definition leaves out those VCT services that are situated in the community and 
directed to a specific key population. 
A different perspective regarding community-based HTC came from a recent 
European project aimed at promoting early diagnosis of HIV infection in Europe, by 
improving the implementation and evaluation of community-based testing practices. 
This group has come to a widely accepted definition of community-based HTC, namely 
defining it as: ‘any program or service that offers HIV counselling and testing on a 
voluntary basis outside formal health facilities and that has been designed to target 
specific groups of the population most at risk and is clearly adapted for and accessible 
to those communities. Moreover, these services should ensure the active participation 
of the community with the involvement of community representatives either in planning 
or implementing HIV testing interventions and strategies (33).  
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The WHO nonetheless has recognized the need for a rapid scaling up of innovative 
models of HTC beyond health-care-facility based approaches (34). The provision of 
HIV testing and counselling using community-based approaches can improve the 
equality of access and greater uptake of services, while simultaneously contributing to 
the reduction of stigma and discrimination (20, 21).  
A systematic review assessing feasibility, acceptability, and effectiveness of HIV 
testing in community settings in resource-rich countries, found that the most commonly 
targeted group were MSM (35). MSM clients prefer non-clinical settings, non-invasive 
methods, receiving results faster, supportive and non-judgmental services (35, 36). 
Aspects regarding anonymity, confidentiality and free-of-charge tests were also cited 
as important in choosing to test for HIV (35). However, issues have been raised about 
possible breaches in confidentiality, as well as stigma and the ability of community 
services to provide a high professional standard of care (35). Among MSM there was 
concern that providing adequate post-test counselling would be difficult in community 
settings such as bars and clubs. Staff training was highlighted as an important 
component of community testing as it increased the levels of comfort about both the 
testing process and the provision of results in this setting (35). 
In summary, HTC services are crucial to improve access to HIV-related care and 
prevention services, and to provide opportunities for people to reduce their risk of 
acquiring or transmitting HIV (34). The WHO recommends a strategic mix of service 
delivery models to achieve universal and equitable access to HTC, including expanded 
community-based options and innovated strategies reaching facilities, strong linkages 
to prevention, care, and treatment, and support services after testing and the use of 
new HIV testing strategies in high and low prevalence epidemics to assure accurate 
and valid test results (20). 
1.2.3.1. The CheckpointLX model 
CheckpointLX is a community-based centre for anonymous and free rapid HIV testing 
and counselling directed at MSM. Testing and counselling is provided by trained peer-
counsellors (37). It is a project from GAT – Grupo Português de Activistas sobre 
Tratamentos de VIH/SIDA, a Portuguese non-governmental organization (NGO) 
advocating legal and political changes that can have a positive effect on the rights and 
quality of life of those living with HIV, or those most at risk of acquiring the infection 
(38).  
The centre was established in April 2011 aiming to: 
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1. Perform free, anonymous, or confidential HIV screening with rapid tests and 
counselling especially directed to MSM in a peer-based approach;  
2. Early detection of HIV infection in MSM and assurance of effective linkages 
to care to the National Health Service; 
3. Providing specific information for MSM about sexual health and HIV, or 
other sexually transmitted infections; 
4. Produce and disseminate information materials on HIV or other STI 
prevention; 
5. Contribute to epidemiological and behavioural knowledge regarding MSM in 
Portugal by collecting anonymized data. 
CheckpointLX is located at a Lesbian Gay Bisexual Transgender socializing quarter, it 
is publicized in MSM socializing sites such as bars, discos, saunas, sex shops and 
guesthouses, at parties and events of the MSM community, at cruising areas and 
online social networks. The location and the shop-front style promote walk-ins (figure 
2). Promotion materials include flyers, videos, stickers, banners at online social 
networks and prevention kits containing condoms, lubricant and an information card 
about CheckpointLX.  
Although CheckpointLX is intentionally 
devoted to MSM, the centre also receives any 
individual who may seek for the services 
offered. These services, although more 
limited than those available for MSM, may 
include HIV testing, and pre- and post-test 
counselling.  
MSM, when coming to CheckpointLX, find a 
team of trained peer counsellors that provide 
pre- and post-test counselling and who 
perform HIV and syphilis rapid tests. A 
protocol for the referral of individuals who 
have a reactive test for HIV was made with a 
HIV/Infectious diseases clinic in a central 
hospital in Lisbon (Hospital Santo António 
dos Capuchos). In case of a reactive test for syphilis, an internal referral is made to a 
parallel STI clinic service called “Checklist”. It consists of a medical appointment for 
MSM, addressing sexual health and screening for other STI. 
Figure 2: CheckpointLX shop-front style. 
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1.3. COHORT STUDIES IN HIV-NEGATIVE MSM 
1.3.1. Basic concepts of cohort studies 
Cohort studies are observational investigations that can be thought of as natural 
experiments in which outcomes are measured in real world settings. These cohort 
studies have been used since the 19th century as a powerful tool to study determinants 
of diseases (39, 40). In a cohort study, members of a defined population are 
characterized in terms of relevant risk factors or exposures, placed under observation, 
and followed for some time until the disease either develops or not. This design allows 
for the evaluation of both the risk and the rate of disease or disease-related outcomes 
(39). Cohort studies can be classified in two major categories depending on the 
decision to go forward in time from the present or to go back in time to assemble the 
study sample. The first category being concurrent or prospective cohorts, where the 
study is done by going ahead in time from the present, and the second category being 
non-concurrent or retrospective cohorts where the study goes back in time to constitute 
the cohort and follow them up to the present (39, 41). A cohort study is the best way to 
accurately estimate incidence and to characterize the natural history of a disease, and 
can be used to examine multiple outcomes after a single exposure (41). Despite 
disadvantages regarding higher cost and complexity, cohort studies remain of vital 
importance to public health research (39, 40).  
1.3.2. Cohort studies among HIV-negative MSM 
In the context of the HIV epidemic in MSM, several cohort studies have been 
implemented since 1983. A summary of the main characteristics of these cohort 
studies using a prospective design that estimated HIV incidence in MSM who were 
HIV-negative at the time of recruitment are presented in table 1. 
Cohort studies are now implemented in a variety of contexts from high income to low 
and middle income countries, and are being conducted using several approaches in 
recruitment strategies and settings.  
Cohort studies have the potential to deliver important and valuable a most valuable 
public health knowledge (42). In fact, most established knowledge related with HIV 
transmission and pathogenesis has originated from several cohorts targeting key 
populations at higher risk of HIV infection (5). These findings have significantly 
improved our understanding of HIV epidemiology and HIV pathogenesis, by 
characterizing risk factors associated with disease acquisition and progression, and the 
effects of therapy (5, 43). Many of these results have guided public health policies (43). 
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Table 1: Summary of main characteristics of cohort studies using a prospective design with HIV incidence estimates for MSM. 
COHORT NAME 
DESIGN 
SPECIFICITIES 
CITY, 
COUNTRY 
N TOTAL 
PERSON-YEARS OF FOLLOW-
UP 
PERIOD OF 
DATA 
COLLECTION 
MAIN OBJECTIVES 
RECRUITMENT 
STRATEGIES 
SETTING 
FOLLOW-UP FREQUENCY 
MEASUREMENTS 
HIV INCIDENCE 
EUROPE         
Amsterdam 
Cohort Studies 
(ACS) –  Protocol 
2 (8, 44, 45)  
Open cohort 
Amsterdam, 
The 
Netherlands 
1642 MSM (with at least 2 visits 
to December 2009) 
11 223 PY  
October 1984-
present 
1. Investigate 
prevalence, 
incidence and risk 
factors of HIV-1 
infection and AIDS 
2. Investigate 
natural history and 
pathogenesis of 
HIV-1 infection 
3. Investigate the 
effects of 
interventions 
1. ‘Convenience sampling’ 
(brochures/advertisements 
in the STI clinic and other 
MSM meeting places) 
2. ‘Chain referral 
sampling’ 
The Public 
Health 
Service 
3- to 6-monthly follow-up 
1. Epidemiological and social questionnaires 
2. Physical examination 
3. Virological and immunological tests and cell 
storage (selected groups) 
2.0 (1.0-3.7) per 
100 PY in 2009 
Rotterdam MSM-
Cohort study (46, 
47) 
3-year cohort 
Rotterdam, 
The 
Netherlands 
286 MSM aged 18 to 75 
190 MSM followed for 3 years 
Recruitment 
between February 
1999 and February 
2000 – end of 
follow-up in 2003 
1. Monitor the 
cumulative 
incidence of STDs 
and HIV infection in 
MSM 
2. Investigate 
longitudinal 
behavioural 
changes  
3. Monitor the 
increase in both HIV 
infection and STDs 
together with 
behavioural 
determinants 
4. Study whether 
perceived 
susceptibility to and 
severity of infection 
with HIV and STDs, 
as well as 
knowledge of HIV 
infection and STDs, 
were associated 
with incident HIV 
infection and STDs 
1. At STD clinics, gay bars 
and saunas 
2. Advertisements 
in newspapers and gay 
periodicals 
STD clinic of 
the 
Department 
of 
Dermatology 
and 
Venereology, 
Erasmus 
University 
Medical 
Centre 
6-monthly follow-up  
1. Medical history 
2. Demographic and sexual information 
3. Self-administered questionnaire on 
potential psychological predictors 
4. Laboratory testing for HIV, syphilis, 
hepatitis B, Chlamydia and genital herpes  
3.2% 
(cumulative 
incidence) over 
3 years 
(48) Amsterdam, 
The 
Netherlands  
770 homosexual men  
675 injecting drug abusers  
1984/1985 to 1995 1. Assess the HIV 
epidemic in this 
high-risk groups 
Not available Not available Not available 1.0 per 100 PY 
in 1995 
(homosexual 
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men) 
(49) Amsterdam, 
The 
Netherlands  
429 young MSM 1995-October 
1996 
1. Surveillance of 
HIV prevalence and 
incidence  
2. Surveillance of 
sexual risk 
behaviour among 
young homosexual 
men 
Not available Municipal  
Health 
Service 
1. Sexual behaviour questionnaire 
2. Laboratory determination of HIV, hepatitis B 
and syphilis antibodies  
1.0% per year 
NORTH 
AMERICA 
        
The Multicenter 
AIDS Cohort 
Study (MACS) 
(43, 50) 
Ongoing and 
multicentre cohort 
Los 
Angeles, 
Chicago, 
Baltimore 
and 
Pittsburgh, 
in the United 
States 
As of May 2011: 
6972 MSM (3501 HIV-positive of 
who 617 incident)  
86.883 PY of follow-up 
Initiated in 1983 
Recruitment: 
April 1984 to 
March 1985 (4954 
MSM)  
April 1987 to 
September 1991 
(668 MSM) 
October 2001 to 
August 2003 (1350 
MSM) 
1. Elucidate the 
natural history of the 
infection causing 
AIDS  
2. Identify risk 
factors for 
occurrence and 
clinical expression of 
the infection 
3. Establish a 
repository of biologic 
specimens for future 
study 
1. Media publicity 
2. Personal connections of 
both the gay activists and 
early participants in the 
study 
3. previous clinical or 
research contacts 
UCLA 
Northwestern 
University in 
Chicago 
University of 
Pittsburgh 
Johns 
Hopkins 
University in 
Baltimore 
6-monthly follow-up 
1. Questionnaire about medical history, 
behaviour, quality of life, depression, activities 
of daily living and medications.  
2. Neuropsychological screening. 
3. Laboratory testing for HIV antibody (only 
HIV-negative MSM), T-cell subsets and viral 
load.  
4. Storage of cells, serum, plasma and 
Epstein-Barr virus-transformed B-cell lines 
and peripheral blood mononuclear cell pellets.   
Cumulative 
incidence of 
11.3% as up 
1989 (51) 
The San 
Francisco Cohort 
Study (52, 53) 
6-year cohort 
San 
Francisco, 
US 
6875 homosexual and bisexual 
men who had sought evaluation 
for STD 
(397 had follow-up assessment 
of whom 360 were seronegative) 
Recruitment 
between 1978 and 
1980, end of 
follow-up 1984 
1. Study the 
prevalence, 
incidence and 
prevention of 
hepatitis B virus 
infection 
2. Determine the 
incidence and 
prevalence of the 
AIDS, related 
conditions, and 
infection with the 
human T-
lymphotropic virus, 
type 
Ill/lymphadenopathy-
associated virus 
(HTLV-III/LAV). 
Convenience sampling San 
Francisco 
City Clinic 
6- year follow-up 
1. Blood specimens collected and tested for 
HTLV-III/LAV after 
Cumulative 
incidence of 
AIDS of 4.8% in 
men over 35 
years and 2.2% 
in younger men. 
Cumulative 
incidence of 
HTLV-III/LAV of 
66.4%. 
The San 
Francisco Men’s 
Health Study (54, 
55) 
San 
Francisco, 
US 
1034 single men aged between 
25 to 54 years 
411 were HIV-negative and 
homo/bisexual 
Recruitment 
between June 
1984 and January 
1985, end of 
follow-up 
December 1987 
1. Elucidate 
epidemiology and 
natural history of 
AIDS 
Multistage stratified cluster 
sampling 
Study clinic 
University of 
California 
Survey 
Research 
Centre 
Semi-annually follow-up 
1. Intensive interview on demographics and 
behaviour 
2. Physical examination 
3. Laboratory testing for HIV 
5.9 (2.8-9.0) per 
100 PY in the 
first six months 
of 1985 to 0.7 
per 100 PY 
(0.002-3.8) in 
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the last six 
months of 1987 
(56)  
12-month cohort 
study 
Seattle, 
Washington, 
US 
578 MSM, aged 18 or older and 
who have engaged in anal sex in 
the previous year 
384.62 PY of follow-up 
1995 to 1996 1. Ascertain the 
prevalence of STD 
and incidence of 
HIV-1 and STD   
2. Determine risk 
factors acquiring 
STD, including HIV-
1 
Variety of outreach 
methods 
Not available 6-monthly follow-up 
1. HIV/STD risk reduction counselling 
2. Standardized interviews conducted by 
trained interviewers on demographics and 
behavioural 
3. Laboratory testing at baseline for HIV, other 
STI and hepatitis B 
4. STD physical examination 
1.3 per 100 PY 
EXPLORE Study 
(57-59) 
Longitudinal 
randomized 
behavioural 
intervention trial 
Boston, 
Chicago, 
Denver, 
New York, 
San 
Francisco 
and Seattle, 
US 
4295 MSM aged 16 or older and 
who reported having engaged in 
anal sex with 1 or more men in 
the previous year 
Recruitment 
between January 
1999 and  
February 2001 
End of follow-up 
2003 
1. Test a 
behavioural 
intervention in 
preventing 
acquisition of HIV 
infection among 
MSM in the United 
States.  
2. Estimate 
prevalence of risk 
behaviours  
 
1. Advertising 
2. Street and gay 
socializing outreach 
3. Referrals from other 
cohort studies, current 
study  participants, 
community agencies and 
clinics 
4. Internet sites targeting 
MSM, community forums, 
mailings 
5. Recruitment video 
Not available 6-monthly follow-up 
1. Standardized questionnaires on 
demographics, reasons for participating in the 
study, history of sexually transmitted 
diseases, use of post-exposure prophylaxis, 
and histories of counselling and 
psychotherapy. 
2. Audio computer-assisted self-interviewing 
(ACASI) on attitudes toward safer sex, social 
activities within the gay community, 
depression, alcohol and drug use, and sexual 
behaviours. 
3. HIV pre-test counselling 
4. Laboratory testing for HIV antibody for 
herpes simplex virus-2 antibody. Screening for 
urethral and rectal gonorrhoea 
2 weeks after screening post-test counselling 
to receive HIV test result 
2.1 (1.9-2.4) per 
100 PY 
The BROTHERS 
Study – HTPN 
061 (60) 
Multi-site cohort 
Atlanta, 
Boston Los 
Angeles, 
New York 
City, San 
Francisco 
and 
Washington, 
DC, US 
1553 enrolled black MSM aged 
18 or older reporting UAI with a 
men in the past 6 months and 
1164 followed-up 
926 PY of follow-up 
Recruitment: July 
2009 to October 
2010 
End of follow-up: 
December 2011 
1. Evaluate 
feasibility and 
acceptability of a 
multi-component 
HIV prevention 
intervention for 
Black MSM 
2. Prepare for a 
community-level 
randomized trial to 
test the efficacy of 
the intervention in 
reducing HIV 
incidence among 
black MSM  
1. Directly from the 
community or as sexual 
network partners referred 
by index participants. 
2. Community outreach, 
engagement of key 
informants, local 
community-based groups 
3. Print advertising 
4. Online strategies 
Not available 1. Interview administered questionnaire on 
demographics and health-care related 
information 
2. ACASI questionnaire on behaviours, 
perceived racism and sexual discrimination, 
internalised homophobia, depression, social 
support and internalised HIV stigma 
3. HIV rapid testing and pre-test risk reduction 
counselling 
4. Laboratory testing for HIV reactive tests 
confirmation and for gonorrhoea, chlamydia 
and syphilis 
3.0 (2.0-4.4) per 
100 PY 
The Vanguard 
Project (61-63) 
Vancouver, 
Canada 
1024 self-identified gay and 
bisexual men aged 15 to 30 
years 
For HIV incidence estimates 674 
men were considered 
May, 1995 to 
March 2002 (last 
update) 
1. Determine 
whether social 
determinants were 
independent 
predictors of high-
1. Physician’s offices, 
clinics 
2. Outreach 
Clinics, 
Community 
and Health 
Centres 
6-monthly follow-up 
1. Self-administered questionnaire on 
demographics, sexual behaviours and 
substance use 
2. HIV testing 
1.9 (1.3–2.5) per 
100 PY as of 
December 2001 
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1894.34 PY of follow-up risk sexual 
behaviour 
2. Identify 
sociocultural and 
transmission factors 
associated with 
seroconversion  
Omega Cohort 
study (64, 65) 
Open cohort 
Montreal, 
Canada 
1890 MSM aged 16 or older who 
have had sex with another men 
in the preceding year recruited, 
1846 enrolled and 1587  
5121 PY of follow-up 
October 1996 to 
July 2003  
1. Estimate HIV 
incidence and 
identify factors 
associated with 
seroconversion 
among MSM 
(particularly men of 
less than 30 years of 
age) recruited 
mainly outside 
clinical settings of 
Montreal;  
2. Characterize 
changes in sexual 
behaviours over 
time;  
3. Identify 
psychosociosexual 
factors associated 
with each stage of 
sexual behaviour in 
a quantitative 
perspective; 
4. Facilitate the 
transfer of 
knowledge to 
community groups 
involved in HIV 
prevention 
Bilingual publicity 
campaign carried through 
the general and gay press 
before recruitment 
1. 
Community 
organization  
Centre des 
gais et 
lesbiennes 
de Montréal 
2. Three 
private 
medical 
clinics 
serving a 
large MSM 
clientele 
3. 
Community 
health clinic 
6-monthly follow-up 
1. Self-administered and interview-
administered questionnaires on 
demographics, sexual behaviours and 
psychosocial data 
2. Pre-test counselling 
3. Laboratory testing of HIV, hepatitis B (HBV) 
and syphilis  
4. Three weeks after the first appointment, 
participants return to receive their test results 
and post-test counselling. 
0.62 per 100 PY 
(0.41-0.84) 
The Vancouver 
Lymphadenopathy 
-  AIDS Study (66) 
Vancouver, 
Canada 
726 homosexual men of whom 
345 were seronegative 
November 1982 
through October 
1985 
1. Report on the 
epidemiologic 
features of HIV 
seroconversion in 
this population 
At 6 primary care 
practices  
Primary care 
practices 
6-monthly follow-up 
1. Administered questionnaire 
2. Physical examination 
3. Immunologic and HIV antibody testing 
19% (crude 
cumulative 
incidence) 
AUSTRALIA         
Health in Men 
Study (67-70)  
Open community-
based cohort  
Sydney, 
Australia 
1427 gay men who reported 
having sex with other men within 
the 5 years before enrolment in 
the study living in Sidney or 
regularly participating in the gay 
July 2001 to 
December 2004  
18-month 
extension of the 
study starting from 
1. Establish a 
baseline of risk 
practice among 
potential vaccine 
trial participants  
1. Gay venues, events 
and organisations 
2. Snowballing’ through  
friends of  participants 
3.Referrals from earlier 
Not available 1. Annual face-to-face interviews and semi-
annual telephone interviews between annual 
visits on demographics, sexuality and identity, 
sexual behaviour, gay community 
involvement, contact with HIV epidemics, 
0.87 (0.65–1.14) 
per 100 PY  
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community in Sidney January 2006 2. Monitor risk 
practice and HIV 
incidence in the 
context of vaccine 
initiatives  
3. Inform 
community-based 
organisations and 
other agencies 
engaged in health 
promotion about 
men’s current 
understandings of 
vaccine initiatives 
studies and medical 
practitioners 
4. Via magazine 
advertisements and 
websites 
health, drug use, discrimination, HIV vaccines 
attitudes and understandings  
2. Annual testing for HIV  
LATIN AMERICA         
Project Horizonte 
(71) 
Multicentre open 
cohort 
Minas 
Gerais - 
Belo 
Horizonte, 
Brazil 
470 sexually active homosexual 
and bisexual men aged 18 and 
59 years  
10866 PY of follow up 
October 1994 to 
May 1999  
1. Evaluation of 
seroincidence of HIV 
2. Ascertain the role 
of counselling on 
behaviour 
modification 
3. Assess 
willingness to 
participate in future 
HIV vaccine trials 
1. Pamphlets, notices in 
community newspapers, 
radio, and television 
2. At anonymous testing 
centres 
3. By word of mouth 
Infectious 
and Parasitic 
Diseases 
Service of the 
Universidade 
Federal de 
Minas Gerais  
1. Standardized form 
2. Face-to-face core interview on risk 
behaviour for HIV infection and knowledge 
about HIV/AIDS and HIV vaccines 
3. Standardized clinical interview 
4. Physical examination  
5. Laboratory testing for HIV and cell storage 
1.99 (1.18-3.14) 
per 100 PY for 
48 months of 
follow-up  
Project Rio (72-
74) 
Multicentre open 
cohort 
Rio de 
Janeiro, 
Brazil 
647 homosexual or bisexual 
men ranging in age from 18 to 
50 years 
631 PY of follow-up 
January 1994 to 
December 1998 
1. At Municipal health 
centres 
2. Public information 
3. Community activities 
4. Volunteers (snowball) 
Servidores 
do Estado 
Hospital and 
a sexually 
transmitted 
diseases 
clinic, 
Fluminense 
Federal 
University 
1. Initial visit form 
2. Psychological profile 
3. Social behavioural questionnaire 
4. Physical examination 
5. Laboratory testing for HIV, syphilis and 
hepatitis 
3.33 (1.93-4.67) 
per 100 PY 
Project Bela Vista 
(75) 
Multicentre open 
cohort 
São Paulo, 
Brazil 
MSM aged 18 or older 50 years 
who have not used drugs in the 
previous 6 months to recruitment 
August 1994 1. Pamphlets, notices in 
community newspapers, 
radio, and television 
2. At anonymous testing 
centres 
3. By word of mouth 
Instituto 
Adolfo Lutz 
and AIDS 
and STD 
state 
programme 
1. Socio-behavioural interview 
2. Physical examination 
3. Laboratory testing for HIV, syphilis and 
hepatitis  
Not available 
Project Praça 
Onze (76) 
Rio de 
Janeiro, 
Brazil 
753 men with homosexual 
behaviour aged between 18 and 
50 years 
Mean follow-up of 1.5 years 
July 1995 to May 
1997 
1. Identify a high-risk 
population for 
prevention trials 
2. Determine 
suitability of this 
population for 
vaccine and non-
vaccine intervention 
studies 
At HIV testing sites and 
places frequented by gay 
men 
Hospital 
Escola São 
Francisco de 
Assis, a 
teaching 
hospital of 
the Federal 
University of 
Rio Janeiro 
6-monthly follow-up  
1. Extensive face-to-face interview on risk 
behaviours, signs and symptoms of acute HIV 
infection and STD, and attitudes about 
participating in a HIV vaccine trial 
2. Physical examination 
3. Laboratory testing for HIV, other STI and 
Hepatitis  
3.1 (2.1-4.1) per 
100 PY 
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The Buenos Aires 
Cohort (77, 78) 
Buenos 
Aires, 
Argentina 
327 MSM who did not report 
injecting drug use in the 
previous year 
February 2003 to 
December 2004 
1. Assess the 
prevalence, 
incidence, risk 
factors, and 
molecular 
genotyping of HIV-1 
At NEXO’s through a 
convenience sample 
NEXO 
Asociación 
Civil a large, 
gay- 
supporting 
NGO 
6- and 12-monthly follow-up 
1. Sociodemographic, sexual risk behaviour 
data 
2. Laboratory HIV testing  
3. Pre and post-testing counselling. 
Returning 2 week later to receive serological 
results 
3.9 (2.0-6.7) per 
100 PY 
The ALASKA 
Cohort (79) 
Prospective 
cohort and a 
nested case-
control study 
Lima, Peru 1056 high-risk MSM aged 18 or 
older  
971 PY follow-up 
October 1998 to 
May 2000 
1. Prospectively 
evaluate both HIV 
and ulcerative STI 
incidence estimates  
2. Evaluate its 
behavioural and 
biological correlates 
1. Snowball techniques 
2. Outreach by peer 
educators 
At five “gay-
friendly” 
primary 
health care 
public clinics 
6-monthly follow-up 
1. Counsellor driven standardized clinical, 
demographics and behavioural interview 
2. Risk reduction counselling 
3. Laboratory testing for HIV, syphilis and 
other STI.  
3.5 (2.3-4.7) per 
100 PY 
AFRICA          
(80) Pilot cohort Dakar, 
Senegal  
119 MSM who reported having 
anal sex with a man in the 
previous 12 months, aged 18 or 
older, and members of one of 
the known MSM organizations in 
Dakar and lived there for at least 
six months  
Followed for 15 months 
June 
2011 to October 
2012 
1. Assess the 
feasibility of 
implementing and 
retaining participants 
in a community-
driven HIV 
prevention study in 
Senegal. 
2. Describe the 
study participants in 
terms of HIV and 
STI prevalence and 
incidence, risk 
behaviours and 
indicators of social 
capital at baseline 
Conducted by members of 
a community-based 
organization 
Not available 1. Structured survey on demographics and 
behavioural 
2. Medical examination 
3. Laboratory testing for HIV, syphilis and 
hepatitis B virus at two time points 
16.0 (4.6- 27.4) 
per 100 PY  
ASIA         
(81) Bangkok, 
Thailand 
1744 Men aged 18 or older, Thai 
national, Bangkok residents  
who had penetrative male-to-
male sex in the previous six 
months 
April 2006 and 
December 2011 
1. Assess HIV-
prevalence, 
incidence and risk 
factors 
1. At HIV testing services 
and, entertainment venues 
(bars, discos, saunas) 
2. Internet 
3. By word of mouth 
A dedicated 
study clinic in 
a central 
Bangkok 
hospital 
4-monthly follow-up 
1. ACASI on demographic and behavioural 
data 
2. Pre- and post-test HIV and risk behaviour 
counselling 
3. Laboratory testing for hepatitis, anti-herpes 
simplex virus type-1 and 2, syphilis, N. 
gonorrhoea and C. trachomatis and drug use 
5.9 (5.2-6.8) per 
100 PY 
(82)  
12 month cohort 
Shenyang, 
China 
218 MSM aged 18 or older who 
reported at least one male 
sexual partner 
111 PY of follow-up 
August and 
September 2006 
1. Analyse incident 
rates of HIV and 
syphilis  
2. Clarify the 
dynamics of the 2 
epidemics 
3. Provide rationale 
1. At a non-governmental 
organization (NGO) 
2.Referral from MSM 
peers 
Hospital of 
China 
Medical 
University 
12 month follow-up 
1. Interview-administered questionnaires on 
demographics, sexual behaviour, drug use 
and history of STD 
2. Laboratory testing for HIV and Syphilis 
5.4 (2.0-11.3) 
per 100 PY 
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for building 
interventions 
(83)  
12 month cohort 
Beijing, 
China 
507 sexually active HIV-negative 
MSM aged 18 or older 
November 2006 to 
February 2007  
1. Assess correlates 
of the incident 
infections for HIV, 
syphilis and hepatitis 
B virus 
1. Website advertisement 
2. Peer recruiters 
3. Peer referrals 
District HIV 
testing and 
counselling 
clinic 
6- and 12-month follow-up 
1. HIV-STD risk assessment interview 
administered by trained health professionals 
on sociodemographic and behavioural 
information and history of HIV-related 
prevention, counselling and testing 
2. Client-centred pre-testing counselling and 
risk reduction on HIV/syphilis, HBV and other 
STD 
3. Testing for HIV, syphilis and HBV 
4. Post-test counselling when returning for test 
results 
2.6 (1.1-4.1) per 
100 PY 
(84)  
6 month cohort 
Nanjing, 
China 
397 MSM HIV-seronegative 
aged 18 or older who have 
engaged in anal or oral sex with 
a men in the previous 12 months 
136.81 PY of follow-up 
May to July 2007 1. Estimate HIV 
incidence 
2. Investigate the 
mediating effects of 
same sex-related 
risk factors in 
explaining the 
relationships 
between particular 
risk factors and 
seroconversion  
Respondent driven 
sampling 
At a HIV 
clinic at the 
Jiangsu 
Provincial 
Central for 
Disease 
Control and 
Prevention 
6-monthly follow-up  
1. In-person interviews on sociodemographic, 
sexual behaviour information and history of 
STD 
2. Volunteer counselling and rapid testing for 
HIV and syphilis 
 5.12 (1.33-8.91) 
per 100 PY 
(85)  
12 month cohort 
Beijing, 
China 
797 MSM aged 18 or older who 
have had anal or oral sex with 
men in the previous 6 months 
592.98 PY of follow-up 
August to 
December 2009 
1. Assess the HIV, 
herpes simplex 
virus-2 and syphilis 
incidence rate 
among MSM 
2. Identify 
sociodemographic 
and behavioural risk 
factors of HIV 
seroconversion 
among MSM 
1. Website advertisements 
by a NGO AIDS volunteer 
group 
2. Distribution of flyers 
with study-related 
information 
at MSM- frequented 
venues by trained peer 
recruiters 
3. Referral from peers 
study participants  
 6- and 12 month follow-up 
1. Socio-demographic and sexual behaviour 
questionnaire-based interviews  
2. HIV voluntary and counselling testing 
3. Clinical STD examination 
4. Laboratory testing for HIV, syphilis and 
herpes simplex virus-2 available after one 
week 
8.09 (6.92-9.26) 
per 100 PY 
(86)  
12 month cohort 
Beijing,  
Shanghai, 
Kunming, 
Guiyang, 
Chongqing, 
Chengdu, 
Urumqi and 
Nanning, 
China 
1102 young MSM aged 18 to 25 
years  who had anal or oral sex 
with men in the previous 6 
months 
1168.40 PY follow-up 
August 2009 to 
December 2010  
1. Assess the HIV 
incidence rate 
2. Identify risk 
factors for HIV 
infection 
Snowball sampling Local 
Centres for 
Disease 
Control and 
Prevention 
6-monthly follow-up with 878 YMSM and 12-
month follow-up with 902 YMSM 
1. Structured questionnaire- 
based performed by health workers on 
sociodemographic and behavioural 
information and knowledge related to HIV 
2. Laboratory testing for HIV and syphilis 
infections 
Overall -  6.7 per 
100 PY 
Guiyang - 18.9 
per 100 PY 
Beijing - 10.6 per 
100 PY 
Shanghai - 5.6 
per 100 PY 
Kunming - 5.3 
per 100 PY 
Chongqing - 4.9 
per 100 PY 
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Nanning - 4.8 
per 100 PY 
Urumqi - 4.3 per 
100 PY 
Chengdu - 3.9 
per 100 PY 
(87) 
18 month cohort 
Kunming 
capital city 
of Yunnan 
Province, 
China 
378 aged 18 or older who report 
receptive and/or insertive anal 
sex in the past 12 months 
312.10 PY of follow-up 
June 2009 and 
March 2011 
1. Evaluate the 
current HIV 
incidence  
2. Evaluate the 
correlation between 
HIV infection and 
factors including 
nationalities, 
syphilis, illicit drug 
use behaviours etc., 
and HIV subtypes 
and primary drug 
resistance of  
seroconverted MSM 
Approached from NGO 
staff at various venues 
Local MSM 
NGO 
3-monthly follow-up 
1. Interviewer-administrated questionnaires on 
demographics, sexual behaviour, illicit drug 
use and other HIV related factors 
2. Laboratory testing for syphilis and HIV 
3.5 (1.8-6.2) per 
100 PY 
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2. AIMS 
The aim of this thesis is to describe the ongoing Lisbon MSM cohort by providing the 
first estimates of HIV incidence in MSM in Portugal through the following objectives:  
 
1. To describe the setup and design of the Lisbon cohort of MSM and to provide the 
descriptive characteristics at baseline for the participants recruited between April 2011 
and February 2014. 
2. To estimate incidence of HIV infection in a cohort of MSM and to assess how 
changes in risk factors over time predict HIV seroconversion. 
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Abstract 
Background: In recent years, sex between men is gaining special relevance as 
transmission mode of HIV infection in Portugal. Surveillance tools that allow for a better 
description of the distribution and determinants of HIV infection in men who have sex 
with men (MSM) are essential. We set up an open prospective cohort study, The 
Lisbon Cohort of MSM, at a community-based voluntary HIV counselling and testing 
service targeting the MSM population. The main goal of this cohort study is to 
dynamically monitor the burden of disease and its predictors. The cohort is also 
expected to provide important information to improve the provision of HIV testing and to 
ensure timely linkage to care. In this paper, we aimed to describe the design and 
methodological options of the study, as well as the descriptive characteristics at cohort 
entry of participants enrolled between April 2011 and February 2014. 
Methods/Design: The Lisbon Cohort of MSM, established in April 2011, is an 
observational prospective study conducted at a community-based voluntary HIV 
counselling and testing centre in Lisbon, Portugal (CheckpointLX). Men testing 
negative, aged 18 or older who report having had sex with other men are invited to 
participate at follow-up visits scheduled according to their convenience. At each 
evaluation a structured questionnaire is applied by trained peer counsellors and HIV 
and syphilis rapid tests are performed. From April 2011 to February 2014, 3106 MSM 
were eligible to enter the cohort of whom 923 (29.7%) refused to participate. The 
remaining 2183 (70.3%) individuals were enrolled and 804 had at least one follow-up 
evaluation, for a total of 893 person-years of observation. HIV testing prior to cohort 
entry was reported by 82.3% of participants, the most common reasons for the index 
HIV test were: to check health status/routine (81.3%), perception of exposure to HIV 
more than 3 months before (50.5%) and in the previous 3 months (40.7%). Twelve 
percent of MSM reported sexual intercourse with HIV positive men in the previous 12 
months. Approximately eight percent of those who reported a steady relationship had a 
HIV positive partner, of whom 43.7% reported inconsistent condom use. That 
proportion was 71.0% among those unaware of their steady partner’s HIV status. 
Twenty one percent of men who had at least one occasional partner reported no 
condom use in the last sexual encounter and 46.4% reported inconsistent use in the 
previous 12 months. The most referred reason for engaging in unprotected anal 
intercourse was a steady partner (66.2%). Alcohol or drugs use before or during sexual 
intercourse in the previous 12 months was reported by 86.4% of participants.  
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Discussion: Regionally, the follow-up of this cohort of HIV-negative MSM will be a 
valuable tool for the dynamic monitoring of HIV infection in a Southern European 
setting where limited prospective information existed. Within the international context, it 
will additionally allow for a deeper analytical approach on population time trends and 
individual changes in risk factors shaping the epidemic among MSM. Given our 
sampling frame, full generalizability regarding the whole MSM population is not 
expected. However, since selection bias is not expected to change substantially 
throughout the study period, we believe that our methodological option will not preclude 
the estimation of time trends in incidence estimates or of the determinants of 
seroconversion. Ultimately, study results are intended to inform on the real-world 
effectiveness of policies directed to reducing the burden of HIV among MSM. 
Key-words: HIV; Men who have sex with men; Cohort studies; Incidence. 
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Background 
Since the beginning of the HIV/AIDS epidemic in the early 80s, gay, bisexual and other 
men who have sex with men (MSM) have been a core population affected by the 
disease, but also key contributors to the response to it [1, 2]. During the past three 
decades, significant scientific advances and societal efforts in the fields of prevention, 
treatment, care and support have renewed the hope in achieving an AIDS-free 
generation. However, in many high income countries where a decline in overall HIV 
incidence has been observed, a concurrent increase in the number of new cases 
among MSM has been documented [3], namely in the European Union /European 
Economic Area, where the largest increase in new infections in the last decade was 
observed among young MSM [4]. 
In Portugal, HIV/AIDS followed a concentrated epidemic pattern, where the prevalence 
of HIV in the general population is estimated around 0.5%, but it is over 5% in some 
key populations at such as MSM, people who inject drugs, prisoners, and commercial 
sex workers [5]. Among MSM, the prevalence of self-reported infection was estimated 
at 10.9% in the European MSM Internet Survey (EMIS) [6]. This was very similar to the 
10.3% estimate found in a previous interview survey (S Dias, personal communication). 
Portuguese official surveillance data show a 6% annual increase in the number of 
newly-diagnosed HIV cases among MSM from 2005 to 2011, while cases due to 
unsafe injection behaviour and heterosexual intercourse decreased by 22% and by 4% 
respectively, in the same period [7]. In 2012, sex between men accounted for 34.1% of 
all HIV cases reported in men, and 24.1% of all cases. Hence, there is an urgency to 
establish dynamic instruments to monitor HIV incidence and determinants in this 
population if, in fact, we want to succeed in the response to HIV among MSM [1]. 
HIV surveillance must be tailored to the state of the epidemic in each setting and this 
includes the promotion of decentralized surveillance tools that are capable of capturing 
HIV trends and behavioural changes in a more timely and analytical fashion than 
national surveillance systems, which are necessarily heavier structures with limited 
applicability for behavioural research [8].  
Community-based studies of MSM present great challenges, namely when it comes to 
defining a sampling frame [9] due to the clear difficulty in establishing the boundaries of 
the target population itself because of cultural, anthropological, and sociological 
reasons. Traditional sampling strategies designed to ensure representativeness and 
external validity, such as simple random or cluster sampling, are often not efficient to 
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recruit and follow MSM [8-11]. Alternative sampling techniques such as convenience 
sampling in community-based facilities devoted to MSM can be substantially more 
feasible and improve crucial attributes for the success of integrated epidemiological 
surveillance such as simplicity, acceptability of participants, and stability [8-12]. 
The Lisbon Cohort of MSM was assembled as a facility-based open prospective cohort 
in a community-based voluntary HIV counselling and testing service directed to MSM. 
The main objectives of the study are: to quantify the burden of the disease by 
estimating the incidence of HIV infection in MSM and monitoring trends in primary and 
secondary prevention; and to identify strategies to improve the provision of HIV testing 
and timely linkage to care of those who have a reactive test. In this paper we describe 
the design and methodological options of the study and present the descriptive 
characteristics at cohort entry of the participants recruited between April 2011 and 
February 2014. 
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Methods/Design 
The Lisbon Cohort of MSM is an observational prospective study established in April 
2011, designed as an open cohort. Eligible participants are men who have sex with 
men aged 18 or older, who voluntarily seek CheckpointLX for HIV testing and 
counselling and have a negative HIV test result at recruitment. 
Setting 
The cohort is a joint project of GAT Portugal (GAT) and the Institute of Public Health of 
University of Porto (ISPUP). GAT is a non-governmental organization advocating legal 
and political changes that can have a positive effect on the rights and quality of life of 
those living with HIV, or most at risk of acquiring the infection. One of GAT’s projects is 
materialized in CheckpointLX, where the Lisbon Cohort of MSM is recruited. 
CheckpointLX is a community-based centre for anonymous and free rapid HIV testing 
and counselling, directed at MSM, and provided by trained peer MSM counsellors. 
ISPUP is an advanced training and research institution in the Public Health domain. In 
respect to the cohort study, CheckpointLX is responsible for recruitment and data 
collection, while ISPUP provides scientific support, data management and analysis. 
Both institutions were involved in the design and implementation of the cohort protocol 
and both have established an official partnership to guarantee a shared commitment to 
the follow-up of cohort participants and to the periodic dissemination and evaluation of 
research outputs. 
Ethics 
The data collected are confidential, and participants give their written informed consent 
prior to inclusion. The study protocol was approved by the Ethics Committee of São 
João Hospital and Medical School, University of Porto (ID 104/12). 
Funding 
From April 2011 to March 2014, all direct funding for the cohort was provided through 
CheckpointLX, with 80% initially funded by the National HIV/AIDS Coordination 
(Portuguese Ministry of Health), and the remaining 20% from sponsors of GAT which 
include: AIDS Healthcare Foundation; Gilead Science, Lda; Bristol-Myers Squibb; 
Janssen; Abbott Portugal; Merck Sharp and Dohme; ViiV Healthcare; ANF – 
Associação Nacional de Farmácias, Delta Cafés and private donations. Since April 
2014, additional specific funding has been obtained as part of the European 
Commission DG SANCO - Health and Consumers funded Euro HIV EDAT project 
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(grant no. 20131101). From inception, ISPUP has provided contribution through the 
allocation of research staff time and information technology support (programming, 
software, and hardware) to the project. 
Recruitment and follow-up of participants 
Recruitment is generally made on the first visit to CheckpointLX where peer 
counsellors invite all eligible clients to enter the cohort. Eligibility criteria for entering the 
cohort is being a man aged 18 or older, reporting having had sex with other men, and 
having a HIV negative test result. CheckpointLX is publicized in MSM socializing sites 
such as bars, discos, saunas, sex shops and guesthouses, parties and events of the 
MSM community, cruising areas, and online social networks. The centre itself, once 
located at an Lesbian Gay Bisexual Transgender socializing quarter, promotes walk-
ins. Promotion material includes flyers, videos, stickers, banners at online social 
networks and prevention kits containing condoms, lubricant, and an information card 
about CheckpointLX. 
Between April 2011 and February 2014, there were 3301 potential eligible individuals, 
195 (5.9%) of whom had a HIV reactive test at entry and therefore were not included in 
the cohort. The remaining 3106 were eligible to the cohort. Among those 923 (29.7%) 
refused to participate, and 2183 (70.3%) were enrolled in the cohort. As of February 
2014, 804 of the 2183 participants had been re-evaluated at least once, yielding 
approximately 2300 interviews (figure 1). 
Follow-up is intended to take place with intervals of six months, although the exact time 
between visits is adjusted according to the convenience of the participant. Men who 
leave their contact details are invited to come back for follow-up visits through text 
messages or email from CheckpointLX staff. All the remaining participants are 
observed whenever they decide to appear again for testing. End points for follow-up 
are the acquisition of HIV infection or death. In the almost three years since the 
recruitment began, we followed 804 participants for a total of 893 person-years. Median 
time between visits was 208 days (approximately 7 months) and 25th to 75th 
percentiles were 148 to 308 days (approximately 5 to 10 months).  
Study procedures 
Questionnaire 
At each visit a questionnaire is administered by a trained CheckpointLX peer 
counsellor. The questionnaire applied at cohort entry is divided into the following 
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sections: sociodemographic characteristics, HIV testing history, sexual life and 
partners, condom use, use of alcohol and drugs, post-exposure prophylaxis (PEP) and 
other sexually-transmitted infections (STI). Follow-up questionnaires update time-
varying information on all sections. Detailed questionnaire content is presented in table 
1. From those eligible MSM who refuse to participate but agree to provide some 
baseline data, information is collected concerning age, gender, country of origin, 
educational level, HIV testing history, date and result of previous HIV test, sexual 
identity, screening for HIV and syphilis at the index visit to CheckpointLX, and reasons 
for refusal to participate. Questionnaires are identified through a sequential number 
and each participant is identified with a six-digit and four-letter unique code 
corresponding to their date of birth (YYMMDD) and the first two letters of their first and 
last names, which allows for data linkage during follow-up while protecting personal 
identity [9]. Periodically, questionnaires are sent to ISPUP where they are processed 
into a computer-based data management system, and where data are stored and 
analysed. 
Rapid HIV testing 
Rapid testing for HIV-1 and HIV-2 is performed at each visit by the same peer 
counsellor that applies the questionnaire. From April 2011 to April 2012 two rapid tests 
were used, namely the Retrocheck HIV® (QUALPRO DIAGNOSTICS, Goa, India) 
(manufacturer reported Sensitivity= 100.00% and Specificity= 99.75%) and Hexagon 
HIV (Human GmbH, Wiesbaden, Germany) (Sensitivity= 100.00% and Specificity= 
99.50%). Since then only the Alere Determine™ HIV-1/2 (Alere Medical Co., Ltd. 
Chiba, Japan) (Sensitivity= 100.00% and Specificity= 100.00%) has been used 
according to the instructions provided by the manufacturer. In case of a reactive test, 
an outpatient appointment is scheduled for every participant that accepts it at the 
HIV/Infectious diseases clinic at Santo António dos Capuchos Hospital in Lisbon, 
where a confirmatory test is performed. The peer counsellor offers to accompany the 
participant to that appointment. Pre and post-test counselling is offered at every visit. 
Syphilis rapid testing 
Rapid testing for detection of Treponema pallidum antibodies is proposed to every 
individual who reports no prior history of syphilis infection or who is unaware of 
previous infection; in this instance the Alere Determine™ Syphilis TP (Alere Medical 
Co., Ltd. Chiba, Japan) (Sensitivity= 92.31% and Specificity= 100.00%) is used 
according to the instructions provided by the manufacturer. In case of a reactive test a 
medical appointment is proposed and scheduled at CheckpointLX as part of the 
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Checklist STI clinic where a confirmatory test is performed and treatment is prescribed, 
if needed. 
Statistical procedures 
Characteristics of participants at cohort entry are described using absolute frequencies 
and proportions in the case of categorical variables. Means and standard deviation 
(SD) or median and percentiles 25 and 75 (P25-P75) are used, as appropriate, to 
describe continuous variables. Comparisons between groups were performed using the 
chi-square test or Fisher’s exact test when variables were categorical. For continuous 
variables Student’s t-test or ANOVA and Mann-Whitney or Kruskall-Wallis tests were 
used, as appropriate. In data analysis, all possible answer categories are described but 
the missing answers are excluded from the denominator of proportions for each item. 
Characteristics of enrolled population between April 2011 and February 2014  
From April 2011 to February 2014, 2183 participants were enrolled in the study. In the 
same period there were 923 refusals to participate in the cohort. The most common 
reasons for refusing to participate were having no interest in the study (25.7%), not 
having the time (23.5%), and not living in Portugal (18.0%). 
As summarized on table 2, there were significant differences between participants and 
refusals: participants self-identified more frequently as homosexual (83.9% vs. 78.3% 
in refusals, p<0.001); mean (SD) age of participants was 30.8 (9.5) years, significantly 
younger than individuals who refused (mean=31.8, SD=10.6 years, p=0.010); 
participants were more frequently born in Portugal (75.7% vs. 59.0% in refusals, 
p<0.001); and 58.1% of participants had a university degree compared to 51.4% 
among refusals. The proportion of individuals who had a previous HIV test was similar 
between groups (81.9% in participants vs. 83.8% in refusals). 
Characteristics of cohort participants 
Median (P25-P75) number of HIV tests prior to cohort entry was 3 (2-6) and the most 
common reasons for the index HIV test were: to check health status/routine (81.3%), 
perception of exposure to HIV more than 3 months before (50.5%) and in the previous 
3 months (40.7%) (Table 3A). 
Median (P25-P75) age at first anal intercourse (AI) (receptive or insertive) was 18 (16-
22) years, and 1409 (65.2%) men reported having a versatile role on AI, while 553 
(25.6%) reported having only an insertive role and 177 (8.2%) only a receptive role. 
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Twelve percent reported sexual intercourse with HIV positive men in the previous 12 
months (Table 3B). 
In the previous 12 months, 1373 (63.0%) participants had at least one steady partner, 
of whom 108 (7.9%) had a HIV-positive partner, 338 (24.8%) were unaware of their 
steady partner’s HIV status and the remaining 913 (67.0%) had HIV-negative partner. 
More than half of men who had at least one steady partner reported no condom use in 
the last sexual encounter (LSE) and approximately 72.0% reported inconsistent use. 
Among those in a serodiscordant relationship, 43.7% reported inconsistent use of 
condom and that proportion was 71.0% among those unaware of their steady partner’s 
HIV status (Table 3B1). 
Sexual intercourse with at least one occasional partner in the previous 12 months was 
reported by 1860 (85.2%) participants and the median (P25-P75) number of partners 
was 4 (2-10). Twenty one percent of men who had at least one occasional partner 
reported no condom use in the LSE and 46.4% reported inconsistent use. The most 
referred venues where participants usually met their occasional partners were the 
internet (72.2%), discos and gay bars (48.4%) and cruising sites (23.2%) (Table 3B2). 
Condoms were always used for oral sex by 2.3% of participants. Always using 
condoms for AI in lifetime was reported by 652 (32.9%) participants. Among the 1318 
(66.5%) participants who reported not having always used condom for AI the most 
common reasons for engaging in unprotected anal intercourse (UAI) were a steady 
partner (66.2%), a steady partner after testing negative for HIV (47.9%), “reliable” 
persons (39.8%), and being too aroused (37.1%) (Table C). 
Lifetime use of alcohol or drugs before or during intercourse was reported by 1520 
(69.7%) participants, among whom 86.4% reported consumption in the previous 12 
months. The most frequently reported psychoactive substances were alcohol (82.7%), 
poppers (25.6%), and cannabis (23.4%) (Table 3D). 
A little over one third of participants had heard about PEP, and 54 participants (2.7%) 
knew about and had used PEP (Table 3E). 
History of symptoms or diagnosis of any STI in the previous 12 months was reported 
by 216 (9.9%) participants and 1368 (62.8%) never had any symptom or STI. A 
diagnosis of gonorrhoea was reported by 226 (28.9%) participants, of which 54 (20.9%) 
were diagnosed in the previous 12 months. Syphilis had been diagnosed in the 
previous 12 months in 38 (4.7%) participants and before that in 116 (14.3%) 
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participants. Having been diagnosed with Hepatitis C was reported by 10 (0.5%) 
participants (Table 3F), none of whom admitted to inject drugs. 
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Discussion 
The Lisbon Cohort of MSM is the first Portuguese prospective study of MSM in the 
context of HIV incidence, testing, and linkage to care. As an open prospective study, it 
will provide information on the trends of HIV infection and other STIs among MSM in 
Portugal and it will contribute to identify and monitor determinants of infection, including 
risk-taking behaviours.  
Until recently, serological and behavioural evidence on HIV among MSM in Portugal 
had been scarce, apart from the necessarily succinct indicators obtained through 
routine national HIV surveillance. Two recent cross-sectional studies [13, 14] targeting 
MSM in Portugal provided the first population-based estimates of self-reported 
prevalence: 10.9% [6] and 10.3% [14]. In addition to these alarming estimates, both 
studies have raised important concerns regarding the future of the epidemic in Portugal 
supporting the need for a closer monitoring of behavioural and serological indicators 
within a dynamic framework. 
A few cohorts follow seronegative MSM internationally, for instance the Amsterdam 
Cohort Studies (ACS) on HIV infection and AIDS that started shortly after the first 
cases of AIDS had been diagnosed in the Netherlands [15], the Multicenter AIDS 
Cohort Study (MACS) initiated in 1983 in four cities in the United States [16], the 
Omega Cohort Study in Montreal, Canada carried out from October 1996 to July 2003 
[17], the Health in Men (HIM) in Sidney, Australia established in July 2001 [18] and, 
more recently, in 2008 the ITACA Cohort in Barcelona established in a community-
based voluntary HIV testing and counselling centre - the BCN Checkpoint [19]. These 
cohorts have significantly contributed to our understanding of the HIV/AIDS epidemic 
and will likely enable comparisons of findings with those of our newly-developed 
infrastructure. This cohort has the potential to serve as a modern decentralised 
surveillance structure that will provide dynamic information about the burden of the 
epidemics and its determinants in this group. Within our geographical setting, it has the 
potential to enable locally-adapted responses in terms of service provision, namely on 
the development of effective strategies to anticipate diagnosis, and to improve linkage 
to care for individuals who have recently been diagnosed with HIV. The cohort will also 
allow comparisons of behavioural indicators drawn from entry and follow-up 
questionnaires within the international context, since it collects the set of indicators for 
behavioural surveillance among MSM defined by the European Centre for Disease 
Control and Prevention (ECDC) [20]. Finally, a set of specific analytical research 
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objectives will be pursued, with strong emphasis on how contextual and behavioural 
trajectories throughout follow-up may be used to predict the risk of seroconversion. 
The Lisbon Cohort of MSM has a relevant strength in the peer-based approach 
provided by CheckpointLX, in an attempt to promote an adequate response to MSM 
needs, and to be a non-judgmental and an inclusive service, reportedly the preference 
of gay and other MSM for testing services [21]. From a research point of view, this 
approach can also help reduce social desirability bias with regard to information 
collected, and can be more cost effective than interventions based on clinical staff [22]. 
Another strength of the cohort is the assurance of anonymity which is expected to 
influence completeness of reporting and disclosure of risk [9]. In addition, in line with 
the ethical guidelines for surveillance in populations most at risk for HIV, the Lisbon 
Cohort of MSM offers to all participants: timely results, information about HIV and 
AIDS, counselling on HIV prevention and on other health or social needs, linkage to 
treatment and care to the extent possible with local resources and protocols with health 
services for referrals [9]. Furthermore, CheckpointLX peer counsellors accompany 
newly-identified HIV-positive participants to their first appointment at a HIV/Infectious 
disease clinic to boost linkage to care, following the experience of other community-
based centres dedicated to MSM in European countries that have shown have high 
efficiency in HIV detection and linkage to care [23, 24]. 
The Lisbon Cohort of MSM, as a facility-based structure is unlikely to result in a 
representative sample of the source MSM population, which limits the generalizability 
of our findings to the whole community. This is a frequent concern in studies with non-
probabilistic samples, but should not be an argument for not attempting to generate the 
best scientific evidence within real-world constraints. Additionally, by following only 
MSM who seek HIV testing, we are arguably selecting a subgroup that might be on 
average at a higher risk of infection than the general MSM community, thereby 
focusing our attention among a priority subset of the population (even if potentially 
more aware than those not reached by the service). The following comparisons are 
useful to assess the extent of selection bias (Table 4). In the 2007 National Health and 
Sexuality Survey (HSS) [25], which included a representative sample of the Portuguese 
population, 4.7% of adult male individuals reported some kind of sexual contact with 
other men in their lifetime, 3.0% of sexually active men had sex with men in the 
previous 12 months, and 0.9% reported homosexual identity. Despite the 
heteronormative frame still persistent in the Portuguese society [25] the proportion of 
men reporting sex with other men is quite similar to that estimated by the EMIS study, 
where approximately 3.0% of the adult male population living in Portugal were 
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estimated to be MSM [26]. Men in our sample are clearly younger than in the HSS, 
where about 31% were less than 25 years old, while in the HSS, men who have had 
some kind of sexual contact with men in that age strata represent only 9.8%. Men in 
the Lisbon cohort reported more frequently on having a previous HIV test (82.3% vs. 
61.0% in HSS). When compared with EMIS results [13] from a sub-analysis including 
only participants aged 18 or more living in the Lisbon region, men in our sample have 
lower mean age (30.8 vs. 33.4) and lower educational level (58.3% with an university 
degree vs. 61.9%), but report more frequently homosexual identity (84.3% vs. 73.6%), 
migrant status (24.0% vs. 22.6%), previous HIV test (82.3% vs. 77.0%) and lifetime use 
of PEP (2.7% vs. 2.1%). We may assume that we are capturing men who are more 
self-identified as homosexual, which was expected once CheckpointLX is directed to 
this group, and perhaps more aware of HIV risk once frequency of uptake of HIV 
testing is higher than in previous studies. It is important to stress that since 
CheckpointLX promotion strategies remained similar during follow-up, we do not expect 
a change in the extent of selection bias over time which is particularly important for the 
estimation of secular trends of infection and behaviours in the source population [8-10]. 
Participation bias is also a key methodological issue in epidemiological studies. In fact, 
participants in our study are more self-identified as homosexual, more frequently born 
in Portugal, and more educated than those who refused to participate. This implies that 
important data may be missing on a harder to reach subset of the target population. 
However, it is interesting to note that the proportion of a previous HIV test is similar 
between groups suggesting that both groups may have similar perceived high risk of 
acquiring HIV [27, 28].  
Attrition is a main concern in prospective investigations, due to the fact that this is not 
an interval cohort with fixed follow-up times the ability to estimate it in a short time 
frame is limited. However, efforts have been made to minimize dropout rates. 
CheckpointLX peer counsellors ask all participants to provide their email or mobile 
phone contact at the first interview and to update contacts in the follow-up 
assessments. These contacts are used with the consent of participants to send 
reminders at the month of an intended follow-up.  
One other ongoing challenge is the possible behavioural modification by cohort 
participants due to their participation in an investigation, known as Hawthorne effect. 
This aspect also relates to the dual role of CheckpointLX as a healthcare/counselling 
provider and a research structure. Checkpoint’s first priority is that appropriate and 
high-quality pre- and post-test information or counselling is offered [29], and hopefully 
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that will produce a change towards better health empowerment, likely to influence the 
risk of the outcomes being studied [30]. 
Additional note 
We encourage interest from scientists, researchers or students from graduation or 
post-graduation to get involved in data collection and/or analyses, and to raise new 
scientific questions. We also look forward to external collaborations with other cohort 
studies. Requests for data analysis, presentation or publication, must be submitted to 
the Lisbon Cohort of MSM scientific coordination, and will require acknowledgement 
that Lisbon Cohort of MSM has the copyright to the data. All Information is available at 
http://www.checkpointLX.com. 
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Table 1: Content of the questionnaire. 
 Entry Follow-up 
1. Sociodemographic characteristics   
Date of birth   
Gender   
Country of birth   
Educational level   
Employment status   
2. HIV testing   
Ever tested for HIV   
Access to HIV testing result   
Reasons for not testing or not having HIV test result   
Number of previous HIV tests   
Place, date and result of previous HIV test   
Reasons for index test   
3. Sexual life and partners   
Sexual identity   
Age at first anal intercourse   
Role in anal intercourse   
Characteristics of sexual partners in the previous 12 months/since the 
previous visit 
  
a. Steady partner   
Steady partner in the previous 12 months/since the previous visit   
Duration of the relationship with steady partner   
Gender of steady partner   
Sexual practices with steady partner   
Sexual intercourse with other partners   
HIV status of the steady partner   
b. Occasional partner   
Occasional partner in the previous 12 months/since the previous visit   
Number of occasional partners in the previous 12 months/since the 
previous visit 
  
Sexual practices with an occasional partner   
Venues used to meet occasional partners   
c. Sex work   
Having sex for money or drugs in the previous 12 months/since previous 
visit 
  
4. Condom use   
Condom use with a steady partner in the previous 12 months/since the 
previous visit 
  
Condom use with a steady partner in the last anal intercourse   
Condom use with an occasional partner in the previous 12 months/since the 
previous visit 
  
Condom use with an occasional partner in the last anal intercourse   
Condom use for oral sex   
Reasons for not using condom   
Lubricant use for anal intercourse   
5. Alcohol and drugs   
Lifetime use of alcohol or drugs before or during intercourse   
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Frequency of use of alcohol or drugs before or during intercourse in the 
previous 12 months/since the previous visit 
  
Perception of reduction in condom use due to use of alcohol or drugs   
6. Post exposure prophylaxis    
Knowledge of PEP   
Lifetime use of PEP   
Use of PEP in the previous 12 months/since the previous visit   
7. Sexually transmitted infections and Hepatitis   
Lifetime history of STI (symptoms or diagnosis)   
Symptoms of STI in the previous 12 months/since the previous visit   
Lifetime history of STI diagnosis    
Diagnosis of STI in the previous 12 months/since the previous visit   
Immunization status for Hepatitis A and Hepatitis B   
Lifetime history of Hepatitis virus A, B or C diagnosis   
* bisexual men; men with different partners; sex workers; HIV-positive men; injecting drug users; women; 
trios/group sex 
Abbreviations: HIV – Human Immunodeficiency virus; PEP – Post-exposure Prophylaxis; STI - Sexually 
transmitted infections  
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Table 2: Sociodemographic characteristics of participants in the cohort and refusals. 
Abbreviations: HIV: human immunodeficiency virus, SD: standard deviation 
  
 PARTICIPANTS REFUSALS p-value 
 2183 (70.3) 923 (29.7)  
Sexual identity, n (%)   <0.001 
Homosexual 1831 (83.9) 709 (78.3)  
Bisexual 306 (14.0) 151 (16.7)  
Heterosexual 28 (1.3) 37 (4.1)  
Other/Did not know/Rather not 
say 
17 (0.8) 8 (0.9)  
Missing 1 18  
Age, mean (SD) 30.8 (9.5) 31.8 (10.6) 0.010 
Country/Region of origin   <0.001 
Portugal 1573 (75.7) 539 (59.0)  
Brazil 231 (11.1) 160 (17.5)  
Other European country 139 (6.7) 141 (15.4)  
African country 89 (4.3) 27 (3.0)  
Other American country 31 (1.5) 30 (3.3)  
Asia / Middle east / Oceania 9 (0.4) 16 (1.8)  
Rather not answer 5 (0.2) 1 (0.1)  
Missing 107 9  
Educational level   <0.001 
Basic education or less 78 (3.6) 101 (11.3)  
Secondary education 564 (25.9) 288 (32.3)  
Professional training 260 (11.9) 36 (4.0)  
Bachelor 896 (41.0) 341 (38.2)  
Master or Doctoral 373 (17.1) 118 (13.2)  
Other/Rather not answer 10 (0.5) 9 (1.0)  
Missing 2 30  
Previous HIV testing    0.167 
Yes 1650 (81.9) 766 (83.8)  
No 354 (17.6) 145 (15.9)  
Did not know 11 (0.5) 2 (0.2)  
Rather not answer 0 (0.0) 1 (0.1)  
Missing 168 9  
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Table 3A – 3F: Descriptive characteristics of participants at cohort entry 
(3A) HIV TESTING N (%) Missing 
Previous HIV testing (n= 2183)  168 
Yes 1650 (81.9)  
No 354 (17.6)  
Did not know 11 (0.5)  
Rather not answer 0 (0.0)  
Number of previous tests, median (P25-P75) 3 (2-6) 31 
Local of last HIV test (n=1650)  2 
Public network of VCT centres (CAD)  506 (30.7)  
Family doctor (National health service) 311 (18.9)  
Public Hospital (National health service) 182 (11.0)  
Abroad 152 (9.2)  
Private Laboratory 150 (9.1)  
Private Hospital or Clinic 144 (8.7)  
CheckpointLX 79 (4.8)  
Blood donation 45 (2.7)  
Mobile unit 28 (1.7)  
Other 49 (3.0)  
Did not know 2 (0.1)  
Reasons for index test (n=2183) 
(multiple options possible) 
  
To check health status / Routine 1736 (81.3) 49 
Perception of HIV exposure more than 3 months before 1084 (50.5) 38 
Perception of HIV exposure in the previous 3 months 884 (40.7) 9 
Accident with condom use (rupture / left inside) 183 (8.6) 56 
My partner asked me to test for HIV 158 (7.4) 57 
To stop using condom with my partner 149 (7.0) 64 
Partner diagnosed HIV+/Disclosed HIV+ status 138 (6.5) 56 
Possible  window period by the time of the last test 136 (6.4) 61 
Symptoms / Medical indication 58 (2.7) 61 
Other reason 159 (7.3) 0 
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(3B) SEXUAL LIFE AND PARTNERS N (%) Missing 
Age at first anal intercourse, median (P25-P75) 18 (16-22) 216 
Role on anal intercourse  22 
Only insertive 553 (25.6)  
Only receptive 177 (8.2)  
Versatile 1409 (65.2)  
Did not know 2 (0.1)  
Rather not answer 20 (1.0)  
Intercourse with at least one of the following in the 
previous 12 months:  
  
Bisexual men  31 
Yes 732 (34.0)  
No 1145 (53.2)  
Did not know 262 (12.2)  
Rather not say 13 (0.6)  
Men with different sex partners  32 
Yes 1475 (68.6)  
No 491 (22.8)  
Did not know 172 (8.0)  
Rather not say 13 (0.6)  
Sex workers (even if not payed)  32 
Yes 133 (6.2)  
No 1920 (89.3)  
Did not know 85 (4.0)  
Rather not say 13 (0.6)  
HIV positive men   
Yes 259 (12.0) 32 
No 1181 (54.9)  
Did not know 698 (32.5)  
Rather not say 13 (0.6)  
Injecting Drug Users  32 
Yes 16 (0.7)  
No 1958 (91.0)  
Did not know 164 (7.6)  
Rather not say 13 (0.6)  
Women  32 
Yes 287 (13.3)  
No 1851 (86.1)  
Did not know 0 (0.0)  
Rather not say 13 (0.6)  
Trios / Group sex  33 
Yes 585 (27.2)  
No 1549 (72.0)  
Did not know 1 (0.0)  
Rather not say 15 (0.7)  
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(3B1) STEADY PARTNER N (%) Missing 
Steady partner in the previous 12 months (n=2183)  2 
Yes, one 1254 (57.5)  
Yes, more than one 119 (5.5)  
No 798 (36.6)  
Did not know 0 (0.0)  
Rather not answer 10 (0.5)  
HIV status of steady partner (n=1373)  11 
HIV negative 913 (67.0)  
HIV positive 108 (7.9)  
Did not know 338 (24.8)  
Rather not say 3 (0.2)  
Condom use with steady partner   
In the last sexual encounter (n=1373)  70 
Yes 572 (43.9)  
No 718 (55.1)  
Did not know 5 (0.4)  
Rather not say 8 (0.6)  
Frequency in the previous 12 months (n=1373)  69 
Always 364 (27.9)  
Often/Occasionally/Rarely/Never 931 (71.4)  
Rather not say 9 (0.7)  
Frequency in the previous 12 months with HIV positive 
steady partner (n=108) 
 5 
Always 57 (55.3)  
Often/Occasionally/Rarely/Never 45 (43.7)  
Rather not say 1 (1.0)  
Frequency in the previous 12 months with unknown HIV 
status steady partner (n=338) 
 10 
Always 95 (29.0)  
Often/Occasionally/Rarely/Never 233 (71.0)  
Rather not say 0 (0.0)  
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(3B2) OCCASIONAL PARTNERS N (%) Missing 
Occasional partners in the previous 12 months (n=2183)  0 
Yes 1860 (85.2)  
No 312 (14.3)  
Rather not say 11 (0.5)  
Number of occasional partners in the previous 12 months: 
Median (P25-P75) (n=1860) 
4 (2-10) 45 
Having sex for money or drugs in the previous 12 months 
(n=1860) 
 1 
Yes 62 (3.3)  
No 1796 (96.6)  
Did not know 1 (0.1)  
Condom use with occasional partner   
In the last sexual encounter (n=1860)  124 
Yes 1360 (78.3)  
No 367 (21.1)  
Did not know 8 (0.5)  
Rather not say 1 (0.1)  
Frequency in the previous 12 months (n=1860)  123 
Always 925 (53.3)  
Often/Occasionally/Rarely/Never 806 (46.4)  
Did not know 2 (0.1)  
Rather not say 4 (0.2)  
Venues used to meet occasional partners (n=1860)  
(multiple options possible) 
  
Internet 1338 (72.2) 8 
Discos and gay bars 897 (48.4) 7 
Cruising sites 430 (23.2) 10 
Saunas 356 (19.3) 11 
Gymnasium 232 (12.6) 14 
"Dark rooms" (including sex-shops) 129 (7.0) 11 
Sex clubs 92 (5.0) 10 
Other 445 (23.9) 0 
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(3C) CONDOMS N (%) Missing  
Lifetime condom use on oral sex (n=2183)  7 
Always 49 (2.3)  
Often /Occasionally/Rarely/Never 2106 (96.8)  
Rather not say 21 (1.0)  
Lifetime condom use on anal intercourse (n= 2183)  202 
Always 652 (32.9)  
Often /Occasionally/Rarely/Never 1318 (66.5)  
Rather not say 11 (0.6)  
Reasons for not using condom on anal intercourse 
(n=1318) (multiple options possible)  
  
with steady partner 870 (66.2) 3 
with steady partner after testing for HIV and both were negative  629 (47.9) 5 
with a “reliable” person 523 (39.8) 3 
being too aroused 487 (37.1) 6 
condom reduces pleasure 360 (27.4) 5 
with a partner that declares he is HIV negative  303 (23.1) 7 
not having condoms in that moment  261 (19.9) 5 
if he has used alcohol or drugs  226 (17.2) 5 
condom interrupts sexual intercourse  201 (15.3) 5 
does not like using condoms  205 (15.6) 5 
condom makes him loose erection  188 (14.3) 4 
with a partner that does not want to use 124 (9.4) 5 
being in a sex venue without condoms available  59 (4.5) 6 
condoms are expensive  40 (3.0) 6 
with a partner that declares undetectable viral load  37 (2.8) 5 
allergy to latex  24 (1.8) 6 
other reasons  77 (5.8) 0 
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(3D) ALCOHOL AND DRUGS N (%) Missing 
Lifetime use of alcohol or drugs before or during 
intercourse (n=2183) 
 1 
Yes 1520 (69.7)  
No 662 (30.3)  
Use of alcohol or drugs before or during intercourse in the 
previous 12 months (n=1520) 
 62 
Yes 1260 (86.4)  
No 175 (12.0)  
Did not know 4 (0.3)  
Rather not answer 19 (1.3)  
Ever used alcohol or drugs before or during intercourse in 
the previous 12 months (n=1520) (multiple options possible) 
  
Alcohol 1254 (82.7) 4 
Poppers 389 (25.6) 2 
Cannabis 329 (23.4) 113 
Cocaine 236 (15.5) 1 
Ecstasy 123 (8.1) 3 
Viagra/Cialis/similar 89 (5.9) 2 
Mephedrone 76 (5.0) 3 
Amphetamines 72 (4.7) 3 
GHB 37 (2.4) 2 
Ketamine 32 (2.1) 2 
LSD 31 (2.0) 3 
Heroine 7 (0.5) 3 
Methadone 8 (0.5) 2 
Others 49 (3.2) 0 
 
(3E) POST-EXPOSURE PROPHYLAXIS (n=2183) N (%) Missing 
Did not know about PEP 1228 (61.2) 175 
Knows but never used  726 (36.2)  
Knows and used 54 (2.7)  
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(3F) SEXUAL TRANSMITTED INFECTIONS AND HEPATITIS   N (%) Missing 
Lifetime history of STI (symptoms or diagnosis) (n=2183)  6 
Yes, in the previous 12 months 216 (9.9)  
Yes, more than 12 months before 593 (27.2)  
No 1368 (62.8)  
STI diagnosed (n=809)    
History of gonorrhoea   
Yes, in the previous 12 months 57 (7.0)  
Yes, more than 12 months before  169 (20.9)  
No 552 (68.2)  
Did not know 31 (3.8)  
History of syphilis   
Yes, in the previous 12 months 38 (4.7)  
Yes, more than 12 months before  116 (14.3)  
No 640 (79.1)  
Did not know 15 (1.9)  
History of condyloma or genital warts   
Yes, in the previous 12 months 68 (8.4)  
Yes, more than 12 months before  22 (2.7)  
No 710 (87.8)  
Did not know 9 (1.1)  
History of chlamydia   
Yes, in the previous 12 months 64 (7.9)  
Yes, more than 12 months before  14 (1.7)  
No 700 (86.5)  
Did not know 31 (3.8)  
History of genital herpes   
Yes, in the previous 12 months 4 (0.5)  
Yes, more than 12 months before  20 (2.5)  
No 771 (95.3)  
Did not know 14 (1.7)  
History of trichomonas   
Yes, in the previous 12 months 3 (0.4)  
Yes, more than 12 months before  1 (0.1)  
No 791 (97.8)  
Did not know 14 (1.7)  
History of lymphogranuloma venereum   
Yes, in the previous 12 months 2 (0.2)  
Yes, more than 12 months before  0 (0.0)  
No 797 (98.5)  
Did not know 10 (1.2)  
Lifetime history of hepatitis diagnosis (n=2183)  12 
History of hepatitis A   
Yes  127 (5.8)  
No 1897 (87.4)  
Did not know 137 (6.3)  
Rather not answer 10 (0.5)  
History of hepatitis B  13 
Yes  52 (2.4)  
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No 2002 (92.3)  
Did not know 106 (4.9)  
Rather not answer 10 (0.5)  
History of hepatitis C  15 
Yes  10 (0.5)  
No 2032 (93.7)  
Did not know 116 (5.4)  
Rather not answer 10 (0.5)  
Vaccination (n=2183)  8 
Hepatitis A   
Yes  827 (38.0)  
No 742 (34.1)  
Did not know 596 (27.4)  
Rather not answer 10 (0.5)  
Hepatitis B  6 
Yes  1603 (73.6)  
No 312 (14.3)  
Did not know 252 (11.6)  
Rather not answer 10 (0.5)  
Abbreviations: HIV: Human Immunodeficiency Virus; VCT: Voluntary counselling and testing GHB: 
Gamma-hydroxybutyric acid; LSD: Lysergic acid diethylamide; PEP: Post-exposure prophylaxis; STI: 
Sexually transmitted infection. 
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Table 4: Comparison of Lisbon Cohort of MSM with previous studies in Portugal. 
 
Lisbon Cohort of 
MSM 
HSS* EMIS study** 
Age 
Mean 
Up to 24 (%) 
 
30.8 
30.9 
 
not available 
9.8 
 
33.4 
28.0 
University degree (%) 58.3 not available 61.9 
Self-reported homosexual identity (%) 84.3 35.9 73.6 
Migrant status 24.0 not available 22.6 
HIV previous test (%) 82.3 61.0 77.0 
Lifetime use of PEP (%) 2.7 not available 2.1 
*between only those men who have had some kind of sexual contact with men 
**sub-analysis of participants aged 18 or more living in the Lisbon region 
Abbreviations: MSM: Men who have sex with men; HSS: Health and Sexuality Survey; EMIS: European 
men who have sex with men survey; HIV: Human immunodeficiency Virus; PEP: Post-exposure 
prophylaxis. 
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Figure 1: Flowchart of enrolments between April 2011 and February 2014 
 
Abbreviations: HIV: Human Immunodeficiency virus.
3301 POTENTIAL ELIGIBLE 
INDIVIDUALS 
3106 ELIGIBLE INDIVIDUALS 
2183 PARTICIPANTS ENROLLED 
804 PARTICIPANTS FOLLOWED-UP 
AS OF FEBRUARY 2014 
(2290 INTERVIEWS) 
1379 PARTICIPANTS NOT YET 
FOLLWED-UP AS OF FEBRUARY 2014  
(1379 INTERVIEWS) 
923 REFUSED TO PARTICIPATE 
195 HAD A HIV REACTIVE TEST 
AT BASELINE (5.9%) 
60 
 
4. CHAPTER II 
  
61 
 
Incident risk factors as predictors of HIV seroconversion in the Lisbon cohort of 
MSM: 2011 – 2014 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
Paula Meireles1, Raquel Lucas1,2, Cláudia Carvalho1,2, Ricardo Fuertes3, João Brito3, 
Maria José Campos3, Luís Mendão3, Henrique Barros1,2 
1 Institute of Public Health of the University of Porto (ISPUP), Porto, Portugal 
2 Department of Clinical Epidemiology, Predictive Medicine and Public Health, 
University of Porto Medical School, Porto, Portugal  
3 Grupo Português de Activistas sobre Tratamentos VIH/SIDA (GAT), Lisboa, Portugal 
 
Corresponding author: 
Paula Meireles 
Departamento de Epidemiologia Clínica, Medicina Preditiva e Saúde Pública 
Faculdade de Medicina da Universidade do Porto 
Al. Prof. Hernâni Monteiro 
4200-319 Porto 
Portugal 
Tel: +351 222 061 820 
Fax: +351 222 061 821 
Email: paula.meireles@ispup.up.pt 
  
62 
 
Abstract 
HIV incidence in men who have sex with men (MSM) is increasing in western 
countries, including Portugal. We aimed to estimate HIV incidence and to assess how 
individual short-term changes in exposures over time predict seroconversion. We 
evaluated participants of an open cohort of HIV-negative MSM enrolled after testing at 
a community-based voluntary HIV counselling and testing centre in Lisbon. At each 
evaluation a structured questionnaire was completed and HIV status was ascertained 
using rapid followed by confirmatory testing. Between April 2011 and February 2014, 
804 MSM were followed for a total of 893 person-years. Predictors of HIV 
seroconversion were identified using Poisson generalized linear regression. The overall 
seroincidence was 2.80/100 person-years (95% CI: 1.89-4.14). Men who 
seroconverted had a higher mean number of tests per year. Seroconversions were 
significantly associated with partner disclosure of HIV status during follow-up, newly-
adopted UAI with a steady partner and being newly-diagnosed with syphilis during 
follow-up. Likewise, sexual intercourse with HIV-positive men, having had a HIV 
positive steady partner at least once during follow-up and persistent UAI with 
occasional partners were predictors of seroconversion. High HIV incidence in this 
cohort of Portuguese MSM is likely to be driven by short-term contextual and 
behavioural changes during follow-up. 
 
Key-words: HIV; Men who have sex with men; Cohort studies; Incidence; Risk factor.  
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Introduction 
A well-established body of potential strategies for the primary prevention of HIV 
infection stems from increased understanding of disease pathogenesis and 
transmission (1, 2). Still, there is evidence of growing HIV incidence among men who 
have sex with men (MSM) in Western Europe, North America and Australia (3-8). 
These trends are unlikely to be explained by changes in surveillance or testing 
practices (3), rather reflecting the fact that MSM remain at higher risk in most countries. 
This is apparent in the burden of newly-diagnosed infections in the European Union 
and European Economic Area: the largest fraction of HIV diagnoses reported in 2012 
was attributable to sex between men (40.4%), followed by heterosexual transmission 
(33.8%), and finally by unsafe injection practices (6.1%) (9).  
This is also the Portuguese pattern: after several years of an HIV epidemic driven by 
unsafe drug injection, sex between men has gained special relevance as a 
transmission mode making up 24.1% of all reported cases in 2012 (10). Two 
pioneering cross-sectional studies (11, 12) targeting MSM living in Portugal collected 
extensive self-reported information, leading to the first alarming estimates of the point 
prevalence of infection: 10.9% (13) and 10.3% (12). 
Monitoring defined cohorts of MSM provides timely estimates of HIV incidence and 
predictors beyond the limited information produced by case reporting or cross-sectional 
surveys. In previous prospective cohorts, the occurrence of new infections has been 
modelled both as a function of factors that directly increase infection risk (frequency of 
unprotected anal intercourse (UAI), viral load of the index partner, presence of sexually 
transmitted infections (STI)), as well as potential markers of exposure, such as number 
of sex partners, substance use, and adverse childhood circumstances (14-19). 
However, how individual exposures change over time and how those changes can 
predict HIV seroconversion remains to be clarified. 
Innovative community-based HIV testing and counselling approaches have been 
developed that target specific population groups at higher risk and involve community 
stakeholders as peer-counsellor and key informants (20). As such, these are privileged 
settings for prospective research on the incidence and drivers of the HIV epidemic 
among MSM, with the ultimate goal of informing realistic preventive strategies.  
The objectives of the present study were to estimate the incidence of HIV infection in a 
cohort of MSM and to assess how individual short-term changes in exposures predict 
seroconversion. 
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Methods 
The Lisbon MSM cohort, established in April 2011, is an observational prospective 
study conducted at a community-based voluntary HIV counselling and testing centre in 
Lisbon, Portugal (CheckpointLX). It was designed as an open cohort, and inclusion 
criteria were: presenting for HIV testing at CheckpointLX, being a man, being aged 18 
years or more, reporting having sex with other men and having a negative HIV test 
result at recruitment. Suspicion of being in the window period was an exclusion 
criterion (n=5 among MSM who filled all inclusion criteria). All eligible individuals were 
invited to enter the cohort by CheckpointLX peer counsellors at their first visit. Follow-
up assessments were scheduled at intended intervals of 6 months, although the exact 
time between visits was adjusted according to the convenience of participants. At each 
visit a structured questionnaire was administered and a rapid HIV test was performed 
by a trained CheckpointLX peer counsellor. Data reported in this study refer to the 
period from April 2011 to February 2014, during which 3301 potential eligible 
individuals presented for testing, 195 (5.9%) of whom had a HIV reactive test at entry 
and therefore were not included in the cohort. The remaining 3106 were eligible to the 
cohort. Among those, 2183 (70.3%) were enrolled in the cohort of whom 804 had at 
least one follow-up evaluation (893.37 person-years of observation) and 923 (29.7%) 
refused to participate. Refusals were less self-identified as homosexual, less frequently 
born in Portugal, and less educated than those who accepted to participate but had a 
similar proportion of HIV testing prior to cohort entry. All participants gave their written 
informed consent and the study protocol was approved by the ethics committee of 
Hospital de São João and Medical School, University of Porto (ID 104/12).  
Rapid HIV testing 
Rapid HIV-1 and HIV-2 testing was performed at each visit. From April 2011 to April 
2012 two commercial kits were used, the Retrocheck HIV® (QUALPRO 
DIAGNOSTICS, Goa, India) (manufacturer-described Sensitivity= 100.00% and 
Specificity= 99.75%) and Hexagon HIV (Human GmbH, Wiesbaden, Germany) 
(Sensitivity= 100.00% and Specificity= 99.50%) and since then, only the Alere 
Determine™ HIV-1/2 (Alere Medical Co., Ltd. Chiba, Japan) (Sensitivity= 100.00% and 
Specificity= 99.75%) has been used. In case of a reactive test, an outpatient 
appointment was scheduled at Santo António dos Capuchos Hospital – HIV/Infectious 
diseases clinic in Lisbon where a confirmatory test was performed. Pre- and post-test 
counselling was offered at each visit. 
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Study instruments and variables 
Structured questionnaires were administered by trained peer counsellors at entry and 
at each follow-up visit collecting data on background and behavioural characteristics, 
according to ECDC and UNGASS guidelines for HIV surveillance (21, 22). For time-
varying information the recall period was the previous 12 months (cohort entry 
questionnaire) or the time since the previous assessment (follow-up visits). Background 
characteristics included age, gender, country of birth, educational level and sexual 
identity. 
Behavioural indicators included information on the following topics: 
 History of previous HIV testing and reasons for index test; 
 Sexual life and partners: age at first anal intercourse, role at anal intercourse, 
characteristics of sexual partners (bisexual men, men with different sexual partners, 
sex workers, HIV-positive men, people who inject drugs, women and trios/group 
sex), steady (number, gender and HIV status, if known) and occasional partners in 
the previous year, having been paid for sex and venues used to meet occasional 
partners; 
 Condom use: frequency of condom use for anal intercourse with steady and 
occasional partners. 
 Use of alcohol or recreational drugs (cannabis, LSD, poppers, heroin and drugs 
typically used at (sex) parties such as ecstasy, amphetamines, mephedrone, GHB, 
ketamine and cocaine) before or during intercourse;  
 Knowledge and use of post-exposure prophylaxis (PPE); 
 History of other STI and hepatitis. 
We were interested in assessing whether intraindividual changes over time in well-
documented determinants of HIV incidence were predictive of seroconversion. Even 
though multiple trajectories of those determinants throughout follow-up were 
theoretically possible, we opted to use information collected at two time points for each 
participant: cohort entry and either the visit of the first HIV positive test (for MSM who 
seroconverted) or the most recent visit (for the remaining MSM). This choice was 
based on two main arguments: 1) the majority (53.8%) of participants had only 2 visits, 
and 2) for participants with three or more visits, using multiple combinations of 
information from all visits did not change the direction of associations or the main 
conclusions, i.e. first and last visit were good surrogates of exposure trajectories during 
follow-up. For this purpose we created new variables for time-varying information that 
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compiled responses from the first visit and the most recent visit, categorized as “Yes to 
No” or “No to Yes” if the information had changed between those visits, and “No and 
No” or “Yes and Yes” if answers were persistent. In case of 24 participants with more 
than 2 visits who preferred not to disclose one or more of the behavioural items at the 
most recent visit we used the information obtained in the preceding visit. This option 
did not alter substantially the magnitude of associations. 
Statistical analysis 
Characteristics of participants at cohort entry were described using absolute 
frequencies and proportions in the case of categorical variables. Means and standard 
deviation (SD) or median and percentiles 25 and 75 (P25-P75) were used, as 
appropriate, to describe continuous variables. In data analysis, the missing category 
was excluded from the denominator for each item. In time-varying information related 
with characteristics of sexual partners the “I do not know” and the “No” options were 
collapsed once the incidence rates in both groups were similar. Unprotected anal 
intercourse (UAI) was defined as not always having used a condom in receptive or 
insertive anal sex. Incidence rates (IR) with 95% confidence intervals (95% CI) were 
estimated with time at risk defined as the period between recruitment and the most 
recent follow-up visit. In MSM who seroconverted, half of the period between the last 
HIV-negative test and the first HIV-positive test was subtracted. 
Poisson generalized linear regression was used to identify predictors of HIV 
seroconversion with the default log link and offset in the variable follow-up time (t). To 
measure the magnitude of associations, crude and adjusted incidence rate ratios (IRR 
and aIRR) and respective 95% CI were computed. Variables whose regression 
coefficient through the Wald test had p<0.10 in the univariate analyses were further 
adjusted for UAI with a steady partner and UAI with occasional partners to estimate 
their direct effects, even though we acknowledge that UAI may be an intermediate step 
in the causal mechanism. For the multivariate analysis significance level was set at 
p<0.05. All statistical analysis were computed with SPSS for Windows, version 22.0 
(SPSS Inc., Chicago, Illinois, USA).  
  
67 
 
Results  
Characteristics of participants at cohort entry 
Background and behavioural characteristics at entry are summarized in table 1. Briefly, 
mean (SD) age was 30.3 (8.9) years; 86.1% of MSM self-identified as homosexual; 
75.0% were born in Portugal and 60.2% had higher education (over 12 years of 
schooling). HIV testing prior to cohort entry was reported by 84.1% of participants. 
Slightly more than two thirds of participants had at least one steady partner, of whom 
46 (9.3%) were in a serodiscordant couple. UAI with a steady partner in the year prior 
to cohort entry was reported by 72.4%; in particular, 40.9% of MSM who had a HIV-
positive partner had UAI in the same period; UAI with one or more occasional partners 
was reported by 43.7% in the same period. Almost one third of men reported having 
used recreational drugs before or during sexual intercourse in the previous year. 
Approximately 2% of MSM had a diagnosis of syphilis in the previous year and 0.4% 
were hepatitis C positive.  
HIV incidence 
Between April 2011 and February 2014, 804 MSM were followed for a total of 893.37 
person-years (ranging from six days to 2.84 years). During follow-up 25 
seroconversions were recorded, yielding an overall incidence of 2.80 per 100 person-
years (95% CI: 1.89-4.14). From these 25 newly-identified cases, 19 (76.0%) were 
effectively linked to care via CheckpointLX. Of the remaining six individuals who did not 
accept referral, three preferred to use means of their own to access health services 
and three did not provide information on clinical follow-up. Participants who 
seroconverted had significantly shorter average follow-up time than those who did not 
seroconvert, but approximately the same number of visits, resulting in a higher mean 
number of tests per year (4.8 vs. 3.9, p=0.012) (table 2). 
Predictors of HIV infection 
Being born before 1970 had a strong though non-significant association with increased 
HIV incidence, whereas the remaining background indicators (country of birth, 
education, sexual identity) had negligible associations with seroconversion. Variables 
that were directly associated with HIV incidence even after adjustment for UAI were: 
reporting partner disclosure of HIV positive status between first and the most recent 
visit (aIRR=5.25; 95%CI 1.60-17.24; p=0.006); sexual intercourse with HIV-positive 
men whether only reported at first visit (aIRR=3.79; 95%CI 1.17-12.24; p=0.026), or 
only at the most recent visit (aIRR=5.99; 95%CI 2.28-15.71; p<0.001); having had a 
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HIV-positive steady partner at least once during follow-up (aIRR=3.28; 95%CI 1.24-
8.68; p=0.017); newly-adopted UAI with a steady partner between cohort entry and the 
most recent visit (aIRR=3.85; 95%CI 1.26-11.78; p=0.018); persistent UAI with 
occasional partners during follow-up (aIRR=3.63; 95%CI 1.38-9.58; p= 0.009) and 
having been newly diagnosed with syphilis between cohort entry and HIV 
seroconversion (aIRR=4.71; 95%CI 1.07-20.71; p=0.040). Having had sex with sex 
workers at least once during follow-up (aIRR=2.60; 95%CI 0.92-7.36; p= 0.072) and 
newly adopting UAI with occasional partners between cohort entry and the most recent 
visit (aIRR=2.79; 95%CI 0.87-8.92; p= 0.084) were associated with borderline 
significance with HIV incidence. 
Significant crude associations with more generic markers of exposure (having started 
to have sex with men four to eight years prior to cohort entry, reporting recent sexual 
intercourse with bisexual men or women and persistent use of recreational drugs at 
both assessments) lost significance after adjustment for UAI with steady and 
occasional partners. Detailed results of HIV predictors are presented in table 3. 
We stratified the analysis of the main determinants of HIV incidence by HIV status of 
steady partner (graph 1). Overall, we observed that MSM who had a HIV-positive 
steady partner during follow-up had higher incidence rates than MSM who did not have 
a HIV-positive partner for all levels of each additional determinant. When compared to 
the lowest risk category of each variable, the greatest increases in HIV incidence were 
found for MSM reporting newly-adopted UAI with a steady partner (IRR=17.29; 95% CI: 
5.00-59.70) and MSM reporting persistent UAI with occasional partners during follow-
up (IRR=14.19; 95% CI: 2.75-73.12).  
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Discussion 
The Lisbon Cohort of MSM provides the first quantification of HIV incidence in MSM in 
Portugal. The overall estimate of 2.80 per 100 person-years is higher than those 
obtained in other European settings (4, 6, 8), and shows worrying ongoing transmission 
of HIV among MSM in Portugal consistently with routine surveillance data. The present 
study also provides evidence that intraindividual changes in the sexual life context - 
particularly partner disclosure of HIV status allied with newly-adopted or persistent UAI 
- are likely driving the HIV epidemic in this cohort of MSM.  
Increased risk of HIV among MSM stems mainly from unprotected anal intercourse, 
and indeed self-reported UAI was an important predictor of HIV seroconversion in this 
cohort, as extensively described in the literature (23). More specifically, persistent UAI 
with occasional partners predicted seroconvertion. Additionally our study specifies that 
changes in UAI adoption with a steady partner during follow-up predicted increased 
HIV incidence, i.e., MSM at higher risk were those who probably abandoned primary 
prevention with a steady partner between cohort entry and the most recent visit. 
Likewise, those that newly adopted UAI with occasional partners were at higher risk, 
even though this association was only marginally significant and of lower magnitude 
than for UAI with a steady partner.   
The role of serodiscordant steady relationships in newly acquiring HIV infection is well-
recognized (24). Safe intercourse between serodiscordant partners requires consistent 
primary prevention, which seems to be to some extent bypassed in this cohort of MSM. 
There is evidence that men within a steady relationship have been overlooked by 
prevention efforts which may have resulted in lower perceptions of risk and increased 
confidence of remaining HIV-negative (25). Previous studies have concluded that MSM 
with steady partners engage in UAI as way to show their love, intimacy, and trust 
toward one another as well as to strengthen their relationship commitment and 
satisfaction (25). It is unknown whether MSM might benefit from prevention strategies 
addressing the couple’s joint serostatus (concordant positive, concordant negative, or 
serodiscordant).  
As for the timing of transmission, among MSM who seroconverted and had a HIV 
positive steady partner during follow-up, approximately half reported their disclosure of 
HIV (whether previously diagnosed or not) between baseline and the most recent visit. 
This suggests that a substantial fraction of transmission to the index partner in this 
cohort might occur during the acute infection stage of the steady partner, when the risk 
of transmission is highest (26, 27). Nevertheless, we cannot exclude the contribution of 
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older infections from partners with suboptimal testing or treatment coverage. Indeed, 
previous studies in Portuguese MSM found that 37.1% of HIV-positive MSM presented 
to care with CD4 count<350/mm3 and, and 39.0% either had detectable viral load or 
were unaware of viral load at the time of the questionnaire (28).  
Regardless of the relative contribution of older or newer infections to incident 
transmission, our results clearly indicate some degree of bypassing of primary 
prevention and a shift towards risk management. This is also reflected in our finding of 
associations between being newly diagnosed with syphilis during follow-up and HIV 
seroconversion. Those incident circumstances (newly-adopted UAI with a steady 
partner, newly-disclosed HIV-positive partner, and newly-diagnosed syphilis) may then 
function as quantitative markers of the short-term risk of infection. 
Conversely, other behavioural factors whose associations with seroconversion were 
independent of measurement timing may be regarded as less specific predictors of 
incident HIV. Such examples were the time since the beginning of sexual life, sexual 
intercourse with bisexual men or sex workers and persistently using recreational drugs. 
These were also associated with higher HIV incidence, even though such associations 
were probably largely mediated by UAI. The number of sexual partners in the year prior 
to cohort entry was not associated with increased HIV incidence. These findings 
highlight that, rather than extensively characterizing the type or number of partners, 
targeted inquiring about UAI in this context seems to be more accurate to predict HIV 
risk.  
In line with this, accurate self-perception of HIV risk and use of testing as a risk 
management strategy are plausible in this cohort, as also shown by the observation 
that MSM who seroconverted had shorter intervals between follow-up visits and higher 
mean number HIV tests per time unit. 
So far, none of the background variables predicted HIV risk in this cohort of Portuguese 
MSM. However it should be highlighted that higher HIV incidence was found in MSM 
born before 1970. Older MSM were previously described at higher risk of acquiring HIV 
from a steady partner (8) and may underestimate vulnerability since they remained 
uninfected up to the present (29). In contrast with previous studies and national and 
European surveillance data (5, 30) younger MSM were not clearly identified as at 
higher risk for HIV, but that could be related to different patterns of use of the 
CheckpointLX by younger generations. 
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Methodological options and limitations of this study should be addressed. The cohort is 
a facility-based sample, where men are invited to participate when presenting for 
testing. This raises two main issues, one that relates to self-selection and participation 
and the other to service provision itself.  
First, this design option is unlikely to result in a representative sample of the source 
MSM population, which limits the generalizability of our findings to the whole 
community. When compared with data from the 2007 National Health and Sexuality 
Survey (HSS) (31), MSM in our sample are clearly younger, much more self-identified 
as homosexual (86.3% vs. 35.9% of those men who reported some kind of sexual 
contact with men) and report a history of HIV testing more frequently (84.7% vs. 61.0% 
in HSS). Nevertheless, by setting up a cohort study in a community-based voluntary 
counselling and testing site we expect to reach MSM on average at higher risk of 
infection than the general MSM community. Thereby it seems reasonable to admit that 
we are focusing our attention on a priority subset of the population in terms of HIV risk 
(even if potentially more aware than those not reached by the service). Additionally, 
since CheckpointLX promotion strategies remained similar during follow-up, we do not 
expect that the extent of selection bias will change substantially over time, which is 
particularly important for the estimation of secular trends of infection and behaviours in 
the source population (32-34). Another important issue is participation bias: the fact 
that approximately 30% of potentially eligible MSM refused to participate implies that 
informative data may be missing on a harder to reach subset of the target population. 
However, the frequency of prior testing was similar between groups, suggesting that 
both may have similar perceived risk of acquiring HIV (35).  
In addition, this is not an interval cohort with fixed follow-up times, rather depending on 
the frequency of service uptake which limits the ability to estimate losses to follow up in 
a short time frame such as the one considered so far in our study. Nevertheless, efforts 
have been made to minimize dropout rates, including active reminders of follow-up 
visits by peer counsellors. Self-reported information is always subject to limitations in 
validity and reliability. However, we are confident that a relevant strength comes from 
the involvement of community stakeholders as technicians and key informants, since 
this strategy increases participation and improves validity and completeness of 
information as well as disclosure of risk, as supported by previous research (34, 36, 
37).  
Finally, despite the high incidence observed, the absolute number of infections is still 
low, resulting in suboptimal statistical power for some comparisons. In the future, with 
72 
 
larger sample size and longer follow-up periods, we expect increased precision of 
estimates. Nevertheless, these estimates are important for two main reasons: 1) they 
draw a first picture of HIV incidence and its drivers in Portuguese MSM about whom 
little was known; 2) they add evidence on the role of changes in individual 
circumstances in newly acquiring HIV to the existing body of prospective evidence from 
a variety of settings.  
The second main issue is the fact that the recruitment site is itself a service whose 
intervention aims not only to anticipate the diagnosis of HIV infection but also to 
provide evidence-based and adapted information which hopefully may modify the risk 
of acquiring HIV. Given the open cohort design we expect that newly-recruited clients 
are especially important to reflect the overall incidence of infection in the community. 
Additionally, regarding the study of the determinants of infection, there seems to be no 
evidence to support that the magnitude or shape of associations will change 
substantially even if the background risk does. 
In conclusion, we found high HIV incidence in this cohort of Portuguese MSM likely to 
be driven by short-term contextual and behavioural changes during follow-up, namely 
newly-adopted UAI with a steady partner, newly-disclosed HIV-positive partner and 
newly-diagnosed syphilis. Serodiscordant steady relationships played a major role in 
predicting HIV seroconversion as well as persistently reporting UAI with occasional 
partners.  
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Table 1: Characteristics at entry of participants followed in the cohort. 
PARTICIPANTS FOLLOWED-UP 804 
BACKGROUND CHARACTERISTICS  
Age (years), mean (SD) 30.3 (8.9) 
Sexual identity, n (%)  
Homosexual 692 (86.1) 
Bisexual/Heterosexual/Other 109 (13.6) 
Rather not answer 3 (0.4) 
Country of origin, n (%)  
Portugal 575 (75.0) 
Other country 190 (24.7) 
Rather not answer 2 (0.3) 
Educational level, n (%)  
Less than higher education (≤ 12 years of school) 317 (39.5) 
Higher education (> 12 years of school) 483 (60.2) 
Other/Rather not answer 3 (0.3) 
HIV TESTING  
Previous HIV testing, n (%)  
No 115 (15.2) 
Yes 636 (84.1) 
Did not know 5 (0.7) 
Number of previous tests, median (P25-P75) 4 (2-7) 
Reasons for index test, n (%)  
(multiple options possible) 
 
To check health status / Routine 602 (77.9) 
Perception of HIV exposure more than 3 months before 426 (54.0) 
Perception of HIV exposure in the previous 3 months 357 (44.8) 
Accident with condom use (rupture / left inside) 65 (8.4) 
Partner diagnosed HIV+/Disclosed HIV+ status 59 (7.6) 
Possible window period by the time of the last test 55 (7.2) 
To stop using condom with my partner 38 (5.0) 
My partner asked me to test for HIV 34 (4.4) 
Symptoms / Medical indication 20 (2.6) 
SEXUAL LIFE AND PARTNERS  
Age at first anal intercourse, median (P25-P75) 18.0 (16.0-21.0) 
Role on anal intercourse, n (%)   
Only insertive 192 (24.1) 
Only receptive 72 (9.0) 
Versatile 525 (66.0) 
Rather not answer 7 (0.9) 
Sex with at least one of the following in the previous 12 months, n (%)   
Bisexual men  
No 420 (53.1) 
Yes 271 (34.3) 
Did not know 98 (12.4) 
Rather not answer 2 (0.2) 
Men with different sex partners  
No 148 (18.7) 
Yes 588 (74.2) 
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Did not know 54 (6.8) 
Rather not answer 2 (0.3) 
Sex workers (even if not payed)  
No 707 (89.4) 
Yes 51 (6.4) 
Did not know 31 (3.9) 
Rather not answer 2 (0.3) 
HIV positive men  
No 401 (50.7) 
Yes 107 (13.5) 
Did not know 281 (35.5) 
Rather not answer 2 (0.3) 
People who inject drugs 4 (0.5) 
No 785 (99.2) 
Yes 4 (0.5) 
Did not know  
Rather not answer 2 (0.3) 
Women  
No 690 (87.2) 
Yes 99 (12.5) 
Did not know 0 
Rather not answer 2 (0.3) 
Trios / Group sex  
No 563 (71.2) 
Yes 224 (28.3) 
Did not know 1 (0.1) 
Rather not answer 3 (0.4) 
Steady partner in the previous 12 months, n (%)  
No 301 (37.4) 
One steady partner 449 (55.8) 
More than one steady partner 52 (6.5) 
Rather not answer 2 (0.2) 
HIV status of steady partner (n=501), n (%)  
HIV negative 310 (62.5) 
HIV positive 46 (9.3) 
Did not know 139 (28.0) 
Rather not answer 1 (0.2) 
Occasional partners in the previous 12 months, n (%) 713 (88.7) 
No 89 (11.1) 
Yes 713 (88.7) 
Rather not answer 2 (0.2) 
Number of occasional partners in the previous 12 months, median (P25-P75) 5 (2-10) 
Having sex for money or drugs in the previous 12 months (n=713), n (%) 19 (2.7) 
No 693 (97.3) 
Yes 19 (2.7) 
Venues used to meet occasional partners (n=713), n (%)  
(multiple options possible) 
 
Internet 522 (73.9) 
Discos and Gay bars 359 (50.8) 
Cruising sites 173 (24.5) 
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Saunas 142 (20.2) 
Gymnasium 94 (13.4) 
"Dark rooms" (including sex-shops) 49 (7.0) 
Sex clubs 32 (4.5) 
UNPROTECTED ANAL INTERCOURSE (UAI), n (%)  
UAI with a steady partner in the previous 12 months (n=501)  
No 130 (27.4) 
Yes 344 (72.4) 
Rather not say 1 (0.2) 
UAI in the previous 12 months with a HIV-positive steady partner (n=46)  
No 26 (59.1) 
Yes 18 (40.9) 
UAI with occasional partners in the previous 12 months (n=713)  
No 375 (56.1) 
Yes 292 (43.7) 
Rather not say 1 (0.1) 
RECREATIONAL DRUGS, n (%)  
Used recreational drugs before or during sexual intercourse in the previous 
12 months 
 
Never 552 (69.9) 
Always/Often/Occasionally/Rarely 238 (30.1) 
POST-EXPOSURE PROPHYLAXIS (PEP), n (%)  
Does not know about PEP 411 (54.7) 
Knows but never used  317 (42.2) 
Knows and used 23 (3.1) 
SEXUALLY TRANSMITTED INFECTIONS, n (%)   
In the previous 12 months:  
Gonorrhea  20 (2.5) 
Syphilis  13 (1.6) 
Condyloma or genital warts 10 (1.3) 
Chlamydia 7 (0.9) 
Genital herpes 1 (0.1) 
Trichomonas 1 (0.1) 
HISTORY OF HEPATITIS, n (%)   
Hepatitis B 18 (2.3) 
Hepatitis C 3 (0.4) 
Abbreviations: HIV: Human Immunodeficiency Virus; UAI: Unprotected anal intercourse; PEP: Post-
exposure prophylaxis. 
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Table 2: Comparison of follow-up time and number of visits between MSM who seroconverted and those 
who did not seroconverted. 
 HIV-positive HIV-negative p-value* 
N 25 779  
Mean time of follow-up (SD) (years) 0.79 (0.50) 1.12 (0.68) 0.018 
Mean number of visits (SD) 2.76 (1.05) 2.85 (1.21) 0.816 
Mean number of visits per year (SD) 4.8 (3.0) 3.9 (5.6) 0.012 
*p-value for independent samples Mann-Whitney test 
Abbreviations: HIV: human immunodeficiency virus; SD: standard deviation. 
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Table 3: Predictors of HIV Incidence. 
  
HIV 
cases 
PY 
HIV 
Incidence 
IRR (95% CI) 
p-
value 
aIRR* (95%IC) 
p-
value 
Mean number of tests per year during follow-up 
       
Less than 2 1 166.74 0.6 1 
 
1 
 
2 5 367.90 1.4 2.27 (0.26-19.39) 0.455 3.40 (0.40-29.33) 0.266 
3 6 215.20 2.8 4.65 (0.56-38.62) 0.155 4.70 (0.51-42.92) 0.170 
4 3 83.49 3.6 5.99 (0.62-57.60) 0.121 10.59 (1.09-103.27) 0.042 
More than 4 10 60.05 16.7 27.77 (3.56-216.92) 0.002 45.30 (5.62-365.00) <0.001 
Background characteristics 
     
Birth cohort 
       
Before 1970 5 109.26 4.6 2.81 (0.76-10.47) 0.123 
  
1970-1979 4 245.75 1.6 1 
   
1980-1989 12 373.74 3.2 1.97 (0.64-6.12) 0.239 
  
1990 or after 4 164.63 2.4 1.49 (0.37-5.97) 0.571 
  
Country of birth 
      
Portugal 18 648.27 2.8 1 
   
Other 7 211.54 3.3 1.19 (0.50-2.85) 0.694 
  
Education (schooling years) 
       
Less than higher education (<= 12 years) 11 357.42 3.1 1.17 (0.53-2.58) 0.692   
Higher education (>12 years) 14 533.74 2.6 1 
   
Sexual identity 
       
Homosexual 22 789.81 2.8 1 
   
Bisexual/Heterosexual/Other 3 100.31 3.0 1.07 (0.32-3.59) 0.908 
  
HIV testing 
       
Number of HIV previous tests at cohort entry 
     
0 0 120.98 0.0 - 
   
1 a 5 14 476.42 2.9 1 
   
More than 5 10 234.47 4.3 1.45 (0.65-3.27) 0.368 
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Reasons for HIV test during follow-up 
       
Concerned with exposure to HIV throughout follow-up 
       
Never 2 163.21 1.2 
    
At least once 22 716.67 3.1 2.51 (0.59-10.65) 0.214 
  
Partner was diagnosed with HIV/Disclosed HIV status throughout follow-up 
       
Persistent No 18 758.15 2.4 1 
 
1 
 
Changed: Yes to No 2 33.42 6.0 2.52 (0.58-10.86) 0.215 1.91 (0.24-15.01) 0.537 
Changed: No to Yes 5 38.48 13.0 5.47 (2.03-14.74) 0.001 5.25 (1.60-17.24) 0.006 
Persistent Yes 0 12.22 0.0 - 
   
Sexual life & partners 
       
Age at first anal intercourse 
       
More than 15 21 693.42 3.0 1 
   
15 or less 3 136.57 2.2 0.73 (0.22-2.43) 0.603 
  
Time since the beginning of sexual life with other men 
       
4 years or less 5 238.32 2.1 1 
 
1 
 
4 to 8 years 10 185.97 5.4 2.56 (0.88-7.50) 0.086 2.57 (0.77-8.54) 0.123 
more than 8 years 9 405.71 2.2 1.06 (0.35-3.16) 0.920 1.09 (0.32-3.70) 0.887 
Role on anal sex 
       
Insertive only 8 213.54 3.7 1 
   
Receptive/Both 17 658.75 2.6 0.69 (0.30-1.60) 0.385 
  
Sexual intercourse throughout follow-up with any of the following: 
       
HIV-positive men 
       
Persistent No 11 672.50 1.6 1 
 
1 
 
Changed: Yes to No 5 78.05 6.4 3.92 (1.36-11.27) 0.011 3.79 (1.17-12.24) 0.026 
Changed: No to Yes 8 74.57 10.7 6.56 (2.64-16.31) <0.001 5.99 (2.28-15.71) <0.001 
Persistent Yes 0 33.72 0.0 - 
   
Bisexual men 
       
Persistent No 10 478.84 2.1 1 
 
1 
 
Changed: Yes to No 2 152.34 1.3 0.63 (0.14-2.87) 0.549 0.71 (0.15-3.32) 0.660 
85 
 
Changed: No to Yes 3 79.66 3.8 1.80 (0.50-6.55) 0.370 2.23 (0.59-8.42) 0.236 
Persistent Yes 8 147.29 5.4 2.60 (1.03-6.59) 0.044 2.12 (0.79-5.66) 0.136 
Men with different sexual partners 
       
Persistent No 3 113.13 2.7 1 
   
Changed: Yes to No 5 194.75 2.6 0.97 (0.23-4.05) 0.965 
  
Changed: No to Yes 2 85.45 2.3 0.88 (0.15-5.28) 0.891 
  
Persistent Yes 13 462.90 2.8 1.06 (0.30-3.72) 0.929 
  
Sex workers (even if not payed) 
       
Never 18 779.22 2.3 1 
 
1 
 
At least once 5 78.92 6.3 2.74 (1.02-7.39) 0.046 2.60 (0.92-7.36) 0.072 
Women 
       
Persistent No 18 743.54 2.4 1 
 
1 
 
Changed: Yes to No 4 64.21 6.2 2.57 (0.87-7.60) 0.087 2.22 (0.74-6.71) 0.156 
Changed: No to Yes 0 11.83 0.0 - 
   
Persistent Yes 1 38.55 2.6 1.07 (0.14-8.03) 0.946 0.69 (0.09-5.34) 0.723 
Trios/Group sex 
       
Persistent No 13 508.19 2.6 1 
   
Changed: Yes to No 0 129.60 0.0 - 
   
Changed: No to Yes 3 84.82 3.5 1.38 (0.39-4.85) 0.613 
  
Persistent Yes 7 134.39 5.2 2.04 (0.81-5.10) 0.129 
  
Steady partner during follow-up 
       
Persistent No 5 180.52 2.8 1 
   
Changed: Yes to No 2 192.56 1.0 0.38 (0.07-1.93) 0.241 
  
Changed: No to Yes 4 145.44 2.8 0.99 (0.27-3.70) 0.992 
  
Persistent Yes 13 360.75 3.6 1.30 (0.46-3.65) 0.617 
  
HIV-positive steady partner during follow-up 
       
Never 16 777.93 2.1 1 
 
1 
 
At least once 8 90.14 8.9 4.32 (1.85-10.08) 0.001 3.28 (1.24-8.68) 0.017 
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Occasional partners during follow-up 
       
Persistent No 2 40.46 4.9 1 
   
Changed: Yes to No 2 146.52 1.4 0.28 (0.04-1.96) 0.198 
  
Changed: No to Yes 1 46.70 2.1 0.43 (0.04-4.78) 0.495 
  
Persistent Yes 18 644.85 2.8 0.56 (0.13-2.43) 0.443 
  
Number of occasional sexual partners in the previous 12 months at cohort entry 
       
<=1 3 125.50 2.4 1 
   
2 to 9 12 408.48 2.9 1.30 (0.35-4.36) 0.749 
  
>=10 6 242.20 2.5 1.03 (0.26-4.14) 0.960 
  
Having sex for money or drugs during follow-up 
       
Never 22 854.61 2.6 1 
   
At least once 1 21.84 4.6 1.78 (0.24-13.19) 0.573 
  
Unprotected anal intercourse (UAI) during follow-up  
       
UAI with a steady partner 
       
Persistent No 5 305.85 1.6 1 
 
1 
 
Changed: Yes to No 4 191.38 2.1 1.28 (0.34-4.76) 0.714 1.10 (0.29-4.11) 0.892 
Changed: No to Yes 10 150.54 6.6 4.06 (1.39-11.89) 0.010 3.85 (1.26-11.78) 0.018 
Persistent Yes 5 194.26 2.6 1.57 (0.46-5.44) 0.473 1.83 (0.53-6.38) 0.340 
UAI with occasional partners 
       
Persistent No 7 388.18 1.8 1 
 
1 
 
Changed: Yes to No 0 148.83 0.0 - 
   
Changed: No to Yes 5 115.29 4.3 2.41 (0.76-7.58) 0.134 2.79 (0.87-8.92) 0.084 
Persistent Yes 10 162.34 6.2 3.42 (1.30-8.97) 0.013 3.63 (1.38-9.58) 0.009 
Venues used to meet occasional partners at cohort entry 
       
Discos & gay bars 
       
No 12 472.08 2.5 1 
   
Yes 13 410.22 3.2 1.25 (0.57-2.73) 0.582 
  
Saunas 
       
No 21 705.35 3.0 1 
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Yes 4 173.20 2.3 0.78 (0.27-2.26) 0.641 
  
"Dark rooms" (including sex-shops) 
       
No 24 815.21 2.9 1 
   
Yes 1 60.58 1.7 0.56 (0.08-4.14) 0.571 
  
Sex clubs 
       
No 24 840.34 2.9 1 
   
Yes 1 39.61 2.5 0.88 (0.12-6.53) 0.904 
  
Internet 
       
No 6 313.65 1.9 1 
   
Yes 19 567.72 3.3 1.75 (0.70-4.38) 0.232 
  
Cruising sites 
       
No 19 675.79 2.8 1 
   
Yes 6 204.17 2.9 1.05 (0.42-2.62) 0.925 
  
Gymnasium 
       
No 21 771.94 2.7 1 
   
Yes 4 103.01 3.9 1.43 (0.49-4.16) 0.514 
  
Sexually transmitted infections & Hepatitis 
       
Recent history of syphilis during follow-up 
       
Persistent No 22 858.10 2.6 1 
 
1 
 
Changed: Yes to No 1 12.16 8.2 3.21 (0.43-23.79) 0.254 3.89 (0.47-31.91) 0.206 
Changed: No to Yes 2 21.95 9.1 3.55 (0.84-15.12) 0.086 4.71 (1.07-20.71) 0.040 
Persistent Yes 0 0.00 - - 
   
Recent history of gonorrhoea during follow-up 
       
Persistent No 24 835.79 2.9 1 
   
Changed: Yes to No 0 25.77 0.0 -  
  
Changed: No to Yes 1 30.08 3.3 1.16 (0.16-8.56) 0.886 
  
Persistent Yes 0 0.00 - - 
   
Lifetime history of Hepatitis C reported at cohort entry 
       
No/Does not know 25 874.81 2.9 1 
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Yes 0 2.76 0 - 
   
Lifetime history of Hepatitis B reported at cohort entry 
       
No/Does not know 24 862.89 2.8 1 
   
Yes 1 20.64 4.8 1.74 (0.24-12.88) 0.587 
  
Drugs use before or during intercourse 
       
Use of recreational drugs before or during intercourse during follow-up 
       
Persistent No 9 507.25 1.8 1 
 
1 
 
Changed: Yes to No 2 91.08 2.2 1.24 (0.27-5.73) 0.785 0.92 (0.19-4.38) 0.915 
Changed: No to Yes 5 117.90 4.2 2.39 (0.80-7.13) 0.118 1.63 (0.42-6.28) 0.477 
Persistent Yes 8 155.99 5.1 2.89 (1.12-7.49) 0.029 1.90 (0.70-5.17) 0.209 
Post-exposure prophylaxis at cohort entry 
       
Does not know 14 437.41 3.2 1 
   
Knows but never used 10 392.47 2.5 0.80 (0.35-1.79) 0.582 
  
Knows and used 1 21.15 4.7 1.48 (0.19-11.23) 0.706 
  
Abbreviations: HIV: human immunodeficiency virus; PY: person-years; IRR: incidence rate ratio; aIRR: adjusted incidence rate ratio; CI: confidence interval; UAI: unprotected 
anal intercourse. 
* Adjusted for UAI with a steady partners and UAI with occasional partners during follow-up. 
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Graph 1: Stratified analysis of the main determinants of HIV incidence by HIV status of steady partner  
 
Abbreviations: IRR: incidence rate ratio; 95% CI: 95% confidence interval; UAI: unprotected anal intercourse; HIV: human immunodeficiency virus; ref: reference category 
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6. CONCLUSIONS 
The setup of the Lisbon Cohort of MSM is a stepping-stone for the maintenance of a 
modern decentralised surveillance structure specifically addressing seronegative MSM 
in the context of HIV occurrence, risk factors, testing, and linkage to care.  
Regionally, the follow-up of this cohort of HIV-negative MSM will be a valuable tool for 
the dynamic monitoring of HIV infection in a Southern European setting where limited 
prospective information existed. Within the international context, it will additionally allow 
for a deeper analytical approach on population time trends and individual changes in 
risk factors shaping the epidemic among MSM. Given our sampling frame, full 
generalizability regarding the whole MSM population is not expected. However, since 
selection bias is not expected to change substantially throughout the study period, we 
believe that our methodological option will not preclude the estimation of time trends in 
incidence estimates or of the determinants of seroconversion.  
We found a first estimate of HIV incidence of 3 per 100 MSM-years a high HIV 
incidence. HIV epidemic in this cohort of Portuguese MSM likely to be driven by short-
term contextual and behavioural changes during follow-up, namely, newly-adopted UAI 
with a steady partner, newly-disclosed HIV-positive partner and newly-diagnosed 
syphilis. Serodiscordant steady relationships played a major role in predicting HIV 
seroconversion as well as persistently reporting UAI with occasional partners.  
Ultimately, study results are intended to inform on the real-world effectiveness of 
policies directed to reducing the burden of HIV among MSM. 
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